US20020168433A1 - Method of preparing and using compositions extracted from vegetable matter for the treatment of alcoholism - Google Patents
Method of preparing and using compositions extracted from vegetable matter for the treatment of alcoholism Download PDFInfo
- Publication number
- US20020168433A1 US20020168433A1 US10/136,103 US13610302A US2002168433A1 US 20020168433 A1 US20020168433 A1 US 20020168433A1 US 13610302 A US13610302 A US 13610302A US 2002168433 A1 US2002168433 A1 US 2002168433A1
- Authority
- US
- United States
- Prior art keywords
- composition
- group
- isoflavones
- lignans
- saponins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims description 34
- 235000013311 vegetables Nutrition 0.000 title claims description 8
- 208000007848 Alcoholism Diseases 0.000 title description 2
- 201000007930 alcohol dependence Diseases 0.000 title 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 75
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 75
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 58
- 229930013686 lignan Natural products 0.000 claims abstract description 45
- 235000009408 lignans Nutrition 0.000 claims abstract description 45
- 150000005692 lignans Chemical class 0.000 claims abstract description 44
- 235000017807 phytochemicals Nutrition 0.000 claims abstract description 40
- 229930000223 plant secondary metabolite Natural products 0.000 claims abstract description 40
- 229930182490 saponin Natural products 0.000 claims abstract description 40
- 235000017709 saponins Nutrition 0.000 claims abstract description 40
- 150000007949 saponins Chemical class 0.000 claims abstract description 39
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 36
- 241000196324 Embryophyta Species 0.000 claims abstract description 33
- 150000007965 phenolic acids Chemical class 0.000 claims abstract description 32
- 235000009048 phenolic acids Nutrition 0.000 claims abstract description 29
- 235000005487 catechin Nutrition 0.000 claims abstract description 27
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000001765 catechin Chemical class 0.000 claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 235000004431 Linum usitatissimum Nutrition 0.000 claims abstract description 11
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 9
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 8
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 6
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 6
- 235000015724 Trifolium pratense Nutrition 0.000 claims abstract description 6
- 235000013526 red clover Nutrition 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims description 28
- 235000005911 diet Nutrition 0.000 claims description 20
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 9
- -1 lanciresinol Chemical compound 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 244000269722 Thea sinensis Species 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 230000000378 dietary effect Effects 0.000 claims description 7
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 7
- 235000006539 genistein Nutrition 0.000 claims description 7
- 229940045109 genistein Drugs 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000033830 Hot Flashes Diseases 0.000 claims description 6
- 206010060800 Hot flush Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 claims description 6
- 235000007240 daidzein Nutrition 0.000 claims description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 6
- 235000012041 food component Nutrition 0.000 claims description 6
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims description 6
- 240000004658 Medicago sativa Species 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 239000012223 aqueous fraction Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 239000005417 food ingredient Substances 0.000 claims description 5
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 235000013616 tea Nutrition 0.000 claims description 5
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 claims description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 4
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000013379 molasses Nutrition 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 235000004239 secoisolariciresinol Nutrition 0.000 claims description 4
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 claims description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 3
- 239000004378 Glycyrrhizin Substances 0.000 claims description 3
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 3
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 claims description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 3
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 239000012466 permeate Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 2
- OGFXBIXJCWAUCH-KPHUOKFYSA-N (+)-isolariciresinol Chemical compound C1([C@@H]2[C@@H](CO)[C@H](CO)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-KPHUOKFYSA-N 0.000 claims description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 2
- MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 claims description 2
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 claims description 2
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 claims description 2
- BVHIKUCXNBQDEM-JSNMRZPZSA-N (3s,4r,5s)-5-(4-hydroxy-3-methoxyphenyl)-3-[(4-hydroxy-3-methoxyphenyl)methyl]-4-(hydroxymethyl)oxolan-3-ol Chemical compound C1=C(O)C(OC)=CC(C[C@]2(O)[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-JSNMRZPZSA-N 0.000 claims description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 claims description 2
- AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 claims description 2
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 claims description 2
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 claims description 2
- IDGXIXSKISLYAC-WNTKNEGGSA-N Medicagenic acid Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C IDGXIXSKISLYAC-WNTKNEGGSA-N 0.000 claims description 2
- NYDZRKZVFLLTLO-UHFFFAOYSA-N Neoolivil Natural products C1=C(O)C(OC)=CC(C2C(C(CO)C(O2)C=2C=C(OC)C(O)=CC=2)CO)=C1 NYDZRKZVFLLTLO-UHFFFAOYSA-N 0.000 claims description 2
- BVHIKUCXNBQDEM-UHFFFAOYSA-N Olivil Natural products C1=C(O)C(OC)=CC(CC2(O)C(C(OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-UHFFFAOYSA-N 0.000 claims description 2
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 claims description 2
- QMGSCYSTMWRURP-UHFFFAOYSA-N Tomatine Natural products CC1CCC2(NC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(O)C%10O)C8O)C(O)C7O QMGSCYSTMWRURP-UHFFFAOYSA-N 0.000 claims description 2
- 229940074360 caffeic acid Drugs 0.000 claims description 2
- 235000004883 caffeic acid Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 claims description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 2
- 235000012734 epicatechin Nutrition 0.000 claims description 2
- 229940114124 ferulic acid Drugs 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 2
- 235000001785 ferulic acid Nutrition 0.000 claims description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 229960005219 gentisic acid Drugs 0.000 claims description 2
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 claims description 2
- 235000008466 glycitein Nutrition 0.000 claims description 2
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 claims description 2
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 claims description 2
- OEZZQOVAJDAVSJ-UHFFFAOYSA-N isolariciresinol Natural products COc1cc(ccc1O)C1C(CO)C(CO)Cc2cc(O)c(OC)cc12 OEZZQOVAJDAVSJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical class OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000000055 matairesinol Nutrition 0.000 claims description 2
- RNXYRAQIZQGUIK-UHFFFAOYSA-N matairesinol Natural products COc1cc(CC2OCC(=O)C2Cc3ccc(O)c(OC)c3)ccc1O RNXYRAQIZQGUIK-UHFFFAOYSA-N 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims description 2
- FLDQIFMZAMYFJR-UHFFFAOYSA-N medicagenic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4(C)C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1)C(=O)O FLDQIFMZAMYFJR-UHFFFAOYSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229930189104 soyasapogenol Natural products 0.000 claims description 2
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 claims description 2
- REJLGAUYTKNVJM-SGXCCWNXSA-N tomatine Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@@]1(NC[C@@H](C)CC1)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O REJLGAUYTKNVJM-SGXCCWNXSA-N 0.000 claims description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 2
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims description 2
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims description 2
- 241000208202 Linaceae Species 0.000 claims 4
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 230000000153 supplemental effect Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 108010073771 Soybean Proteins Proteins 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims 1
- 239000001354 calcium citrate Substances 0.000 claims 1
- 229960004256 calcium citrate Drugs 0.000 claims 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims 1
- 239000001362 calcium malate Substances 0.000 claims 1
- 229940016114 calcium malate Drugs 0.000 claims 1
- 235000011038 calcium malates Nutrition 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 229960003951 masoprocol Drugs 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 235000013597 soy food Nutrition 0.000 claims 1
- 229940001941 soy protein Drugs 0.000 claims 1
- 235000013337 tricalcium citrate Nutrition 0.000 claims 1
- 240000006240 Linum usitatissimum Species 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 15
- 230000037213 diet Effects 0.000 description 13
- 229940071440 soy protein isolate Drugs 0.000 description 12
- 239000005018 casein Substances 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 5
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 5
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 5
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 5
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 4
- IHNKQIMGVNPMTC-RUZDIDTESA-N 1-stearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C IHNKQIMGVNPMTC-RUZDIDTESA-N 0.000 description 4
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 4
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 4
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 4
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000005418 vegetable material Substances 0.000 description 2
- MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- FJBQYOWYDLEAKI-UHFFFAOYSA-N (2,3-dimethyl-4-phenylbutyl)benzene Chemical group C=1C=CC=CC=1CC(C)C(C)CC1=CC=CC=C1 FJBQYOWYDLEAKI-UHFFFAOYSA-N 0.000 description 1
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical group OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- JDJPNKPFDDUBFV-UHFFFAOYSA-N O-Desmethylangolensin Chemical compound C=1C=C(O)C=CC=1C(C)C(=O)C1=CC=C(O)C=C1O JDJPNKPFDDUBFV-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 235000018734 Sambucus australis Nutrition 0.000 description 1
- 244000180577 Sambucus australis Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229940106582 estrogenic substances Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002272 genistein Chemical class 0.000 description 1
- 229930004065 genistein derivative Natural products 0.000 description 1
- 150000002273 genistein derivatives Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 235000006826 lariciresinol Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940107524 soy germ Drugs 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 229930188627 soysaponin Natural products 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
- A23V2250/21172—Soy Isoflavones, daidzein, genistein
Definitions
- This invention relates to compositions extracted from vegetable matter and more particularly to phytochemicals, including saponogenins and saponins, catechins, lignans, phenolic acids, catechins and isoflavones, and especially those extracted from a family of plants including soy, flax, tea, and cocoa and methods of using these compositions as nutritional supplements or food additives.
- phytochemicals including saponogenins and saponins, catechins, lignans, phenolic acids, catechins and isoflavones, and especially those extracted from a family of plants including soy, flax, tea, and cocoa and methods of using these compositions as nutritional supplements or food additives.
- Plant materials are known to contain a number of classes of organic low molecular weight compounds which exert bioactivity in various animals. Historically, these compounds have been considered to be somewhat non-nutritive, however, recent scientific evidence now suggests these compounds may play an important role in the maintenance of health, in chemoprevention, and in the mitigation of certain conditions or diseases associated with the circulation of sex hormones, including seed disorders and vaginal dryness.
- Edible plants normally contained in the diet, or materials used as herbal remedies/dietary supplements, may contain collections of structurally related compounds. These related substances are often unique in their amounts and distribution when compared among various plant sources. The most notable groups of compounds exhibiting bioactivity are known as flavonoids, isoflavones, saponins, lignans, alkaloids, catechins and phenolic acids.
- Soy products contain high amounts of isoflavones and saponins.
- Unrefined diet grains include plants such as wheat, psyllium, rice, flax and oats that contain lignans. Cocoa contains catechins and phenolic acids Certain non-dietary plants are also sources of the same chemical molecules, such as lignans and isoflavones in kudzu root or red clovers Isoflavones and lignans act as weak estrogenic substances. Tea plants are also a rich source of phytochemicals, including catechins and phenolic acids.
- Isoflavones can be used alone to treat or prevent breast cancer, prostate cancer, skin cancer, and colon cancer or as mechanism inhibitors Isoflavones alone may also reduce or prevent various symptoms related to the onset and duration of menopause, including hot flashes and osteoporosis Isoflavones alone may also be effective in certain cardiovascular applications, including heart disease, reducing cholesterol-lipid levels, modulating angiogenesis, and other vascular effects Moreover, isoflavones alone have been implicated in reducing headaches, dementia, inflammation, and alcohol abuse, as well as immunomodulation.
- Lignans alone have been implicated in preventing or treating breast cancer, prostate cancer and colon cancer as well as reducing hot flashes, preventing osteoporosis and showing antiviral potential. Lignans also have antimitotic and fungicidal activity
- Saponins alone have been implicated in preventing or treating skin cancer, colon cancer, reducing serum cholesterol, and in immunomodulation and antiviral activity. Saponins also exhibit antioxidant effects and act as free radical scavengers
- Isoflavones which are heterocyclic phenols, are understood to include the soy compounds genistin, daidzin and glycitein, as well as biochanin A, equol, formononetin, and o-desmethylangolensin and natural derivatives thereof These compounds and their aglycone or de-methylated aglycone forms, such as genistein and daidzein, are believed to have similar activities once they are ingested They are sometimes referred to as phyto-estrogens
- Lignans are defined to be compounds possessing a 2,3-dibenzylbutane structure. They include matairesinol, secoisolariciresinol, lariciresinol, isolariciresinol, nordihydroguataretic acid, pinoresinol, olivil, other compounds which may be precursors of enterolactone and enterodiol and modifications thereof, including diglucosides.
- Phenolic acids include p-hydrobenzoic acid, protocatechuic acid, and vanillic acid.
- Other phenolic acids are chlorogenic acid, caffeic acid, ferulic acid, gallic acid, sinapic acid, syringic acid, coumaric acid, cinnamic acid, gentisic acid, salicylic acid, hydroxy benzoic acid and hydroxy phenyl acetic acids and derivatives This list of phenolic acids should be understood to include the various isomers and derivatives found in the natural vegetable source
- Catechins or flavan-3-ols, include epigallocatechin, catechin, epicatechin and gallocatechin.
- Saponogenins are C-27 sterols in which the side chain has undergone metabolic changes to produce a spiroketal. Saponogenins occur naturally as saponins, which are 3-O-glycosides of the parent steroid or triterpenes Digitonin from Digitalis is a saponin.
- Saponins include glucosides of sapogenin such as triterpenoids or steroids and saccharides such as glucose, arabinose, galactose or glucuronic acid
- Typical examples of leguminous saponins are glycyrrhizin (glycyrrhetinic acid+glucuronic acid) contained in Glycyrrhiza glahra , soysaponin contained in soybean and alfalfasaponin contained in Medicago sativa .
- Saponins also include chemical entities identified as triterpene phenols such as tomatine, soyasapogenols A, B, C, D, E and F, ginsengoside fraction 3 and 4, medicagenic acid, hederagenin, glycyrrhizin digitonin, quillaja saponin, lucernic acid and zahnic acid.
- triterpene phenols such as tomatine, soyasapogenols A, B, C, D, E and F, ginsengoside fraction 3 and 4, medicagenic acid, hederagenin, glycyrrhizin digitonin, quillaja saponin, lucernic acid and zahnic acid.
- the natural modifications of these compounds found in the vegetable source are also included in this identification
- An object of this invention is to provide a convenient way for individuals to consume isoflavones, lignans, saponins, catechins and/or phenolic acids, either as a nutritional supplement or as an ingredient in a more traditional type of food.
- An other object of this invention is to provide an optimized extract composition of phytochemicals which is in sufficient concentration to be delivered in an easy to consume dosage such as a pill, tablet, capsule, liquid or ingredient in a food
- Yet another object of this invention is to prepare the phytochemical extract to be delivered as a topical application in a cream or lotion
- the isoflavones, lignans, saponins, catechins and/or phenolic acids are dispersed and suspended in a suitable liquid or gel matrix to render a stable cream or lotion as the delivery vehicle.
- a further object of this invention is to provide an extract concentrate which is closely similar in chemical composition to the chemical entities found in the natural plant source
- the isoflavones, lignans, saponins, catechins and/or phenolic acids are extracted from a suitable vegetable source to render a composition which is substantially more concentrated than the original material and by more than 5 times in one or more of the desired bioactive components
- This extract may be used alone or combined with one or more other plant extracts to produce the optimized composition. Further, this extract composition may be formulated with one or more other dietary, nutrients, such as vitamins, minerals, amino acids, etc., to provide a nutritional supplement further optimized for a desired health effect All these ingredients may be combined with necessary binders, excipients, preservatives, colors and the like known to those in the industry in order to produce a suitable tablet, capsule, pill, liquid, cream, powder or food ingredient.
- phytochemicals may be packaged and provided in final form by means known to the supplements and food ingredient industries.
- the materials are intended to provide health and well-being benefits
- the improved composition is obtained by fractionating a plant source high in isoflavones, lignans and other phytochemicals such as defatted soybean flakes, soy molasses, soy whey, red clover, alfalfa, flax, cocoa, tea, or kudzu root These may be fractionated along or in combination with these other plants known to be high in the various isoflavones, lignans, saponins, catechins and phenolic acids
- the fractionation results in substantially removing water, carbohydrates, proteins, and lipids from the source material
- the fractionation method may be preferably that disclosed in co-pending U.S. Pat. No. 5,702,752 or U.S. Pat. No. 4,428,876, or an extraction using ethyl acetate or n-butanol may be used.
- U.S. Pat. No. 5,702,752 is assigned to the assignee of this invention.
- the preferred composition is an improvement over known commercial materials regarding the amount of phytochemicals per gram of substance and the amounts of different phytochemicals present which affect psychologic function.
- the resulting composition is expected to comprise in a preferred form: between 5% and 95% isoflavones, between 0% and 70% lignans, and between 2% and 70% saponins and sapogenins
- the composition will be extracted from soy
- the composition will contain a ratio of (saponins plus saponogenins) to isoflavones from 1 100 to 100 1, with the isoflavones consisting predominantly of naturally occurring derivatives of genistein and/or its precursor biochanin A and daidzein and/or its precursor formononetin, with a ratio of the genistein derivatives to daidzcin derivatives from 100 1 to 1 100
- the isoflavones are predominantly glycosylated derivatives.
- compositions ratios may be readily vaned by changing the plant source or by combining several plant sources for extraction
- phytochemical combinations are more efficacious for certain health effects, the particular composition will also vary
- isoflavones lignans, and saponins can be used advantageously to treat or prevent various cancers, including breast cancer, prostate cancer, skin cancer, and colon cancer
- Isoflavones or lignans can alleviate menopausal-related symptoms such as hot flashes and osteoporosis as well as alleviate symptoms associated with menstruation. This is further believed to be due to their estrogenic activity It is believed that the improved composition described here will alleviate these symptoms even more effectively.
- isoflavones positively affect various cardiovascular-related conditions, including heart disease, cholesterol (saponins also positively affect cholesterol), angiogenesis and other vascular effects. It is believed that the improved composition will produce results for these cardiovascular conditions at least as beneficial as those hitherto known and at a reduced cost.
- isoflavones As explained earlier, isoflavones, lignans, and saponins are known to individually positively affect various neurological and immunological symptoms. It is believed that the improved composition will result in alleviating neurological and immunological symptoms at least as well as those compounds hitherto known and at a reduced cost. Moreover, it would be expected that some synergism would arise out of the combination described herein.
- the improved composition may be administered orally, parenterally, for instance, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation or by application of an aerosol spray to mucous membranes, or to the skin by an ointment or a cream.
- Administering the improved composition may be done with any suitable carrier, in solid or liquid dosage form such as tablets, capsules, powders, soft gels, solutions, suspensions, emulsions, ointments, or creams.
- the improved composition may also be administered as a food supplement or as a food ingredient.
- the amount of the improved composition administered will vary depending on the person, the mode of administration, and the desired result.
- An effective amount is expected to be 10 mg to 2000 mg/per dose.
- composition provided for in this patent may be used to prepare tablets or other dosage forms.
- An example of a capsule preparation is provided in Example 2
- a 600 mg dry compression tablet was prepared containing a total of 125 mg of isoflavones concentrate (50 mg isoflavone compound) Included in the tablet formulation was a source of calcium and magnesium.
- Dry compression tablets were produced by first blending the following ingredients: 4 kg of the improved composition (39 83% isoflavones), 1 91 kg sorbitol, 0 095 kg magnesium stearate, and 13.11 kg dicalcium phosphate in a 120 quart capacity Hobart mixer This blend of ingredients was then dry compressed at 1 ton pressure with a Stokes BB2 simple press into tablets having a total weight of 600 mg containing 125.53 mg of the improved composition and therefore 50 mg of total isoflavones.
- a photochemical concentrate may be provided in a single dosage form, a skin cream or as a food ingredient added to conventional food in amounts from 10 mg to 2000 mg/per dose, the purpose of which is to exert a positive effect on health and well being
- benefits include: cancer prevention, estrogen and sex hormone related maladies, inhibition of the pituitary-thyroid-gonadotrophic axis, alcohol dependency reduction, modulation of the cardiovascular, immune and nervous systems, antiviral effects and analgesic effects.
- Two-piece gelatin capsules were produced by filling the receiving end of the empty size “0” capsules with 0.106 g of the improved composition (44 35% isoflavones) and closed with the capping end, providing a capsule containing 47 2 mg of total isoflavones.
- the improved composition containing the glycoside forms of isoflavones, has as one aspect an improved solubility at body temperature over the previously described compositions containing the aglycoside forms.
- glycoside forms are at least 4 57 and 13.32 fold higher in concentration at 37° C. than their corresponding aglycone forms, respectively
- the modifications made to the isoflavones are to remove the carbohydrate attached to the isoflavones moiety. This modification renders the isoflavone less soluble in water. Maintenance of the natural modification, glycosylation, enhances solubility. This fact is shown in the comparative solubility chart of Table 5 This chart shows that the genistin isoflavone is 4 6 times higher and the daidzin isoflavone is 13.3 times higher than the corresponding non-glycosylated form. Higher solubility can lead to better bioavailability to intestinal organisms.
- the glycosylation does not inhibit absorption in the gut because the intestinal microflora convert the glycone form to the aglycone form before absorption occurs
- the ethanolic fraction was then evaporated under vacuum at 70° C., resulting in an aqueous fraction of 1186 g
- the aqueous fraction was combined with 1000 g of water and mixed.
- the mixed sample was then ultra-filtered through a 5000 molecular weight cutoff membrane, resulting in a 767 g permeate fraction and a retentate fraction of 1283 g.
Abstract
A composition is prepared by extracting phytochemicals from plant matter. This composition is enriched preferably in isoflavones, lignans, saponins, catechins and phenolic acids. Soy is the preferred source of these chemicals: however, other plants may also be used, such as red clover, kudzu, flax, and cocoa. The composition is a dietary supplement for treatment of various cancers, pre- and post-menstrual syndromes, and various other disorders.
Description
- This is a formal application that replaces provisional application Serial No. 60/060,549 filed Oct. 2, 1997
- This invention relates to compositions extracted from vegetable matter and more particularly to phytochemicals, including saponogenins and saponins, catechins, lignans, phenolic acids, catechins and isoflavones, and especially those extracted from a family of plants including soy, flax, tea, and cocoa and methods of using these compositions as nutritional supplements or food additives.
- Plant materials are known to contain a number of classes of organic low molecular weight compounds which exert bioactivity in various animals. Historically, these compounds have been considered to be somewhat non-nutritive, however, recent scientific evidence now suggests these compounds may play an important role in the maintenance of health, in chemoprevention, and in the mitigation of certain conditions or diseases associated with the circulation of sex hormones, including seed disorders and vaginal dryness.
- Edible plants normally contained in the diet, or materials used as herbal remedies/dietary supplements, may contain collections of structurally related compounds. These related substances are often unique in their amounts and distribution when compared among various plant sources. The most notable groups of compounds exhibiting bioactivity are known as flavonoids, isoflavones, saponins, lignans, alkaloids, catechins and phenolic acids.
- Epidemiology studies relating diet to disease suggest that dietary components may predispose populations to reduced risk of certain diseases. Far eastern populations consuming soy have reduced rates of breast, prostate and colon cancers and coronary heart disease, while populations in Finland have reduced rates of prostate cancer. Researchers are just now studying the specific compounds in the diet to understand the basis for the epidemiological observations
- Among the various plants consumed in the diet, several are rich sources of phytochemicals Soy products contain high amounts of isoflavones and saponins. Unrefined diet grains include plants such as wheat, psyllium, rice, flax and oats that contain lignans. Cocoa contains catechins and phenolic acids Certain non-dietary plants are also sources of the same chemical molecules, such as lignans and isoflavones in kudzu root or red clovers Isoflavones and lignans act as weak estrogenic substances. Tea plants are also a rich source of phytochemicals, including catechins and phenolic acids.
- Isoflavones can be used alone to treat or prevent breast cancer, prostate cancer, skin cancer, and colon cancer or as mechanism inhibitors Isoflavones alone may also reduce or prevent various symptoms related to the onset and duration of menopause, including hot flashes and osteoporosis Isoflavones alone may also be effective in certain cardiovascular applications, including heart disease, reducing cholesterol-lipid levels, modulating angiogenesis, and other vascular effects Moreover, isoflavones alone have been implicated in reducing headaches, dementia, inflammation, and alcohol abuse, as well as immunomodulation.
- Lignans alone have been implicated in preventing or treating breast cancer, prostate cancer and colon cancer as well as reducing hot flashes, preventing osteoporosis and showing antiviral potential. Lignans also have antimitotic and fungicidal activity A plant lignan, the catecholic nordihydro-guataretic acid, was a potent antioxidant once used by the food industry
- Saponins alone have been implicated in preventing or treating skin cancer, colon cancer, reducing serum cholesterol, and in immunomodulation and antiviral activity. Saponins also exhibit antioxidant effects and act as free radical scavengers
- Phenolic acids have shown antioxidant activity
- People who eat a high soy diet show reduction of many of these above-discussed symptoms This suggests that ingesting a combination of these phytochemicals in a ratio such as that found in soy may result in an additive or synergistic effect. However, a high soy diet has some undesirable effects, including flatulence, undesirable taste, and hesitancy among Western consumers to change their lifestyle to incorporate soy in their diets, even for such benefits
- Isoflavones, which are heterocyclic phenols, are understood to include the soy compounds genistin, daidzin and glycitein, as well as biochanin A, equol, formononetin, and o-desmethylangolensin and natural derivatives thereof These compounds and their aglycone or de-methylated aglycone forms, such as genistein and daidzein, are believed to have similar activities once they are ingested They are sometimes referred to as phyto-estrogens
- Lignans are defined to be compounds possessing a 2,3-dibenzylbutane structure. They include matairesinol, secoisolariciresinol, lariciresinol, isolariciresinol, nordihydroguataretic acid, pinoresinol, olivil, other compounds which may be precursors of enterolactone and enterodiol and modifications thereof, including diglucosides.
- Phenolic acids include p-hydrobenzoic acid, protocatechuic acid, and vanillic acid. Other phenolic acids are chlorogenic acid, caffeic acid, ferulic acid, gallic acid, sinapic acid, syringic acid, coumaric acid, cinnamic acid, gentisic acid, salicylic acid, hydroxy benzoic acid and hydroxy phenyl acetic acids and derivatives This list of phenolic acids should be understood to include the various isomers and derivatives found in the natural vegetable source
- Catechins, or flavan-3-ols, include epigallocatechin, catechin, epicatechin and gallocatechin.
- Saponogenins are C-27 sterols in which the side chain has undergone metabolic changes to produce a spiroketal. Saponogenins occur naturally as saponins, which are 3-O-glycosides of the parent steroid or triterpenes Digitonin from Digitalis is a saponin. Saponins include glucosides of sapogenin such as triterpenoids or steroids and saccharides such as glucose, arabinose, galactose or glucuronic acid Typical examples of leguminous saponins are glycyrrhizin (glycyrrhetinic acid+glucuronic acid) contained inGlycyrrhiza glahra, soysaponin contained in soybean and alfalfasaponin contained in Medicago sativa. Saponins also include chemical entities identified as triterpene phenols such as tomatine, soyasapogenols A, B, C, D, E and F, ginsengoside fraction 3 and 4, medicagenic acid, hederagenin, glycyrrhizin digitonin, quillaja saponin, lucernic acid and zahnic acid. The natural modifications of these compounds found in the vegetable source are also included in this identification
- A need exists for an improved composition consisting substantially of isoflavones, lignans, saponogenins, saponins, and/or phenolic acids which will produce improved results over any of these taken alone. Furthermore, a need exists for a composition in which the beneficial phytochemicals are enriched as compared to their original source. This permits individuals to conveniently consume such phytochemicals as a nutritional supplement or as a food additive
- An object of this invention is to provide a convenient way for individuals to consume isoflavones, lignans, saponins, catechins and/or phenolic acids, either as a nutritional supplement or as an ingredient in a more traditional type of food.
- An other object of this invention is to provide an optimized extract composition of phytochemicals which is in sufficient concentration to be delivered in an easy to consume dosage such as a pill, tablet, capsule, liquid or ingredient in a food
- Yet another object of this invention is to prepare the phytochemical extract to be delivered as a topical application in a cream or lotion In this form, the isoflavones, lignans, saponins, catechins and/or phenolic acids are dispersed and suspended in a suitable liquid or gel matrix to render a stable cream or lotion as the delivery vehicle.
- A further object of this invention is to provide an extract concentrate which is closely similar in chemical composition to the chemical entities found in the natural plant source
- In keeping with this aspect of the invention, the isoflavones, lignans, saponins, catechins and/or phenolic acids are extracted from a suitable vegetable source to render a composition which is substantially more concentrated than the original material and by more than 5 times in one or more of the desired bioactive components
- This extract may be used alone or combined with one or more other plant extracts to produce the optimized composition. Further, this extract composition may be formulated with one or more other dietary, nutrients, such as vitamins, minerals, amino acids, etc., to provide a nutritional supplement further optimized for a desired health effect All these ingredients may be combined with necessary binders, excipients, preservatives, colors and the like known to those in the industry in order to produce a suitable tablet, capsule, pill, liquid, cream, powder or food ingredient.
- These phytochemicals may be packaged and provided in final form by means known to the supplements and food ingredient industries. The materials are intended to provide health and well-being benefits
- The improved composition is obtained by fractionating a plant source high in isoflavones, lignans and other phytochemicals such as defatted soybean flakes, soy molasses, soy whey, red clover, alfalfa, flax, cocoa, tea, or kudzu root These may be fractionated along or in combination with these other plants known to be high in the various isoflavones, lignans, saponins, catechins and phenolic acids The fractionation results in substantially removing water, carbohydrates, proteins, and lipids from the source material The fractionation method may be preferably that disclosed in co-pending U.S. Pat. No. 5,702,752 or U.S. Pat. No. 4,428,876, or an extraction using ethyl acetate or n-butanol may be used. U.S. Pat. No. 5,702,752 is assigned to the assignee of this invention.
- Other extraction processes, which may be used alone or in combination, include differential solubility, distillation, solvent extraction, adsorptive means, differential molecular filtration and precipitation
- The preferred composition is an improvement over known commercial materials regarding the amount of phytochemicals per gram of substance and the amounts of different phytochemicals present which affect psychologic function.
- These natural substances have been consumed in food sources for long periods of time and more closely relate to the substances consumed which provide the basis for the epidemiological evidence for health benefits Additional benefits may be derived from improved physical properties relative to phytochemicals chemically modified from their original food source form
- The resulting composition is expected to comprise in a preferred form: between 5% and 95% isoflavones, between 0% and 70% lignans, and between 2% and 70% saponins and sapogenins In a more preferred form, the composition will be extracted from soy In another preferred form, the composition will contain a ratio of (saponins plus saponogenins) to isoflavones from 1 100 to 100 1, with the isoflavones consisting predominantly of naturally occurring derivatives of genistein and/or its precursor biochanin A and daidzein and/or its precursor formononetin, with a ratio of the genistein derivatives to daidzcin derivatives from 100 1 to 1 100 Preferably, the isoflavones are predominantly glycosylated derivatives.
- The composition's ratios may be readily vaned by changing the plant source or by combining several plant sources for extraction Thus, as further study shows which phytochemical combinations are more efficacious for certain health effects, the particular composition will also vary
- It is known that isoflavones, lignans, and saponins can be used advantageously to treat or prevent various cancers, including breast cancer, prostate cancer, skin cancer, and colon cancer
- It is believed that the improved composition will provide increased benefits in the form of chemoprevention. Recent experiments appear to confirm this belief
- An initial series of animal studies was made to investigate the effects of dietary soy products on the growth of s c. (SUBCUTANEOUS) Implanted LNCaP in male SCID mice A high isoflavones-containing soy protein isolate (SPI) (2 0 mg isoflavones/g SPI) is provided by Protein Technology International (St Louis, Mo.) A soy phytochemicals extract, soy phytochemicals concentrate (SPC) which contains 28 5% total soy isoflavones and a diverse amount of other soy phytochemicals, is provided by Archer Daniels Midland Company (Decatur, Ill.) These materials were used to prepare six experimental diets Table 1 shows ingredients of the diets
- Eight-week-old male SCID mice were s c. injected on the right flank with 2×106 LNCaP cells from hosts, randomized into six groups (n=10) and assigned to one of the experimental diets Food intake, body weight, and tumor volume were measured. At the termination of the experiment, blood samples were collected and serum separated for PSA analysis. An aliquot of tumor tissues was formalin-fixed, paraffin-embedded, and cut into 4 μm sections for in situ histochemical detection of apoptotic cells, and immunohistochemical analyses of angiogenesis and proliferation. Another aliquot was prepared for cell lysates for western blot to determine the expression of apoptosis-related gene products.
- Table 2 summaries the effects of treatment on food intake, body weight, isoflavone intake and tumor volume Soy products did not significantly after food intake or body weight. Compared to casein-fed controls, tumor volumes from mice treated with SPI (20%), SPC (1 0%), and SPI and SPC (1 0%) were reduced by 12%, 28% (P<0 04), or 40% (P<0 005), respectively Factorial analysis indicated that there was no significant effect of protein source on tumor growth. Linear regression analysis indicated that tumor volumes were inversely correlated to total dietary isoflavones (Tumor volume (cm3)=−0008+2.121×Isoflavones (mg), R2=0 76, p<0 03).
- Table 3 shows the effects of SPC at 1 0% of the diet on apoptosis, proliferation, and angiogenesis of tumors from a pilot study. It indicates that dietary supplementation of soy phytochemicals inhibits the growth of LNCaP tumor in vivo by enhancing apoptosis and inhibiting proliferation of tumor cells. Its inhibitory effect on tumor angiogenesis is not significant which may be due to small sample size (n=2)
- Results from in vivo study showed that genistein and soy phytochemical concentrate inhibited secretion to PSA by LNCaP cells into media PSA concentrations were reduced 68% and 74% by 25 and 50 μM of genistein treatment respectively, and 31% and 42% by 25 and 50 μM of soy phytochemical concentrate treatment respectively.
TABLE 1 Diel 1 Diel 2 Diel 3 Diel 4 Diel 5 Diel 6 casein SPI Casein/LSPC SPI/LSPC Casein/HSPC SPI/HSP SPI 0 200 0 200 0 200 Casein 200 0 200 0 200 0 DL-methionine 3 3 3 3 3 3 Corn starch 150 150 150 150 150 150 Sucrose 500 500 500 500 500 500 Cellulose, BW200 50 50 50 50 50 50 Corn oil 50 50 50 50 50 50 Mineral Mix, S100011 35 35 35 35 35 35 Vitamin Mix, V100011 10 10 10 10 10 10 Choline Bitartrate 2 2 2 2 2 2 Soy phytochemicals 0 0 2 2 10 10 Total (g) 1000 1000 1002 1002 1010 010 (isoflavones, 0 245 341 586 705 950 mg/kg diet) -
TABLE 2 Final body weight, total food intake, total isoflavone intake, and tumor volume Treat- Food intake Total Tumor volume ment Body weight grams/m isoflavone (cm3) Casein 22.4 ± 46 6 ± 3 1 0.00 ± 0 00 2.32 ± 0.312 0.51 SPI 23.1 ± 0.7 46 2 ± 2.8 17 00 ± 6.37 2.06 ± 0 32 Casein/ 21.4 ± 0.7 41 2 ± 3 4 14 03 ± .14 1.88 ± 0.35 LSPC SPI/ 22.6 ± 0.6 50.1 ± 4 7 29.36 ± 2.76 1.66 ± 0 29* LSPC Casein/ 22.2 ± 0.7 44 8 ± 6.1 76 38 ± 10 40 1.64 ± 0.22* HSPC SPI/ 22.0 ± 0.6 47 5 ± 1.7 92.53 ± 3.22 1.39 ± 0.30** HSPC -
TABLE 3 Effects of treatment on apoptotic index (AI, % TUNEL), proliferation index (PI, % PCNA Staining) and angiogenesis (microvessel density) Microvessel Treatment AI (% TUNEL) PI (% PCNA) Density Control (n = 2) 6.07 ± 0.88 60 1 ± 1.1 12.5 ± 3.8 Casein/HSPC (n = 2) 10 75 ± 0 54 51 7 ± 1 3 9 7 ± 0 7 P value <0 02 <0 01 >0 05 - Values are means=SE.
- In summary, preliminary results indicate that soy products inhibit the s c. growth of LNCaP tumor in SCD mice, possibly via induction of apoptosis, and inhibition of angiogenesis and proliferation.
- Isoflavones or lignans can alleviate menopausal-related symptoms such as hot flashes and osteoporosis as well as alleviate symptoms associated with menstruation. This is further believed to be due to their estrogenic activity It is believed that the improved composition described here will alleviate these symptoms even more effectively.
- Also, isoflavones positively affect various cardiovascular-related conditions, including heart disease, cholesterol (saponins also positively affect cholesterol), angiogenesis and other vascular effects. It is believed that the improved composition will produce results for these cardiovascular conditions at least as beneficial as those hitherto known and at a reduced cost.
- As explained earlier, isoflavones, lignans, and saponins are known to individually positively affect various neurological and immunological symptoms. It is believed that the improved composition will result in alleviating neurological and immunological symptoms at least as well as those compounds hitherto known and at a reduced cost. Moreover, it would be expected that some synergism would arise out of the combination described herein.
- The improved composition may be administered orally, parenterally, for instance, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation or by application of an aerosol spray to mucous membranes, or to the skin by an ointment or a cream.
- Administering the improved composition may be done with any suitable carrier, in solid or liquid dosage form such as tablets, capsules, powders, soft gels, solutions, suspensions, emulsions, ointments, or creams. The improved composition may also be administered as a food supplement or as a food ingredient.
- The amount of the improved composition administered will vary depending on the person, the mode of administration, and the desired result. An effective amount is expected to be 10 mg to 2000 mg/per dose.
- The composition provided for in this patent may be used to prepare tablets or other dosage forms. An example of a capsule preparation is provided in Example 2 The higher the concentration of the active component, the easier it is to form a tablet or emulsion This leads to an added ability to incorporate other dietary nutrients An example would be to prepare a phytochemical tablet which incorporates calcium and vitamin E as a supplement to maintain bone health and/or reduce post menopausal symptoms such as hot flashes In an example of this embodiment, a 600 mg dry compression tablet was prepared containing a total of 125 mg of isoflavones concentrate (50 mg isoflavone compound) Included in the tablet formulation was a source of calcium and magnesium.
- Dry compression tablets were produced by first blending the following ingredients: 4 kg of the improved composition (39 83% isoflavones), 1 91 kg sorbitol, 0 095 kg magnesium stearate, and 13.11 kg dicalcium phosphate in a 120 quart capacity Hobart mixer This blend of ingredients was then dry compressed at 1 ton pressure with a Stokes BB2 simple press into tablets having a total weight of 600 mg containing 125.53 mg of the improved composition and therefore 50 mg of total isoflavones.
- Alternatively, a photochemical concentrate may be provided in a single dosage form, a skin cream or as a food ingredient added to conventional food in amounts from 10 mg to 2000 mg/per dose, the purpose of which is to exert a positive effect on health and well being These benefits include: cancer prevention, estrogen and sex hormone related maladies, inhibition of the pituitary-thyroid-gonadotrophic axis, alcohol dependency reduction, modulation of the cardiovascular, immune and nervous systems, antiviral effects and analgesic effects.
- Two-piece gelatin capsules were produced by filling the receiving end of the empty size “0” capsules with 0.106 g of the improved composition (44 35% isoflavones) and closed with the capping end, providing a capsule containing 47 2 mg of total isoflavones.
- A comparison between various sources of phytochemical preparations is given in Table 4. It is readily seen that the phytochemical components of the composition of the “Isoflavone Concentrate” of this invention is substantially higher than the corresponding amounts in the natural vegetable materials. Notably, the amount of glycone isoflavones and saponins are over 100 times more concentrated compared to the food source and over twenty times more concentrated compared to the germ of the plant which naturally concentrates these phytochemicals. Comparison of the “Isoflavone Concentrate” of this invention to other concentrates shows that the isoflavone fraction predominates in these latter products, reducing the amount of other healthful phytochemicals Additionally, the extraction methods of these other products employ techniques which modify the components, particularly the isoflavones, so that they are not identical to the substances found in the natural vegetable material (U.S. Pat. No. 5,637,562)
- One version of the improved composition, was compared to other previously described compositions The results are shown in Table 4
Isoflavone Isoflavone Glycosides in Aglycones in Genistein/ Phenolic Product Product Product Daidzein Lignans Saponins Acids Example (mg/g) (mg/g) Ratio (mg/g) (mg/g) (mg/g) Improved 401.0 3.37 1.06 to 1 0.2 460.7 25.47 composition Soybean 1.748-2.776a 0.044a-0.075 1.59-2.7 NA 0.9-3.2b SoyFlour 1.969a 0.045a 3.58 0.0013 2.870c (defatted Soy germ 24.32d 0.85d NA 16.7-1.98b NA Productc NA 2.5-6.5c 0.5-3.5 NA NA NA patent (PTI) Productf NA 5.1-14.7f 0.433-3.48 NA NA NA patent (PTI) Productg NA 1.7-3.5g 0.66-2.86 NA NA NA patent (PTI) PTI NA 970 12.8 NA NA NA producth PTI NA 640 2.0 NA NA NA producth Soy 27.6 0.1 1.37 NA NA 5.788 Molasses dried) Navogeni 0.0 550 1-1.7 to 1 NA NA NA - The improved composition, containing the glycoside forms of isoflavones, has as one aspect an improved solubility at body temperature over the previously described compositions containing the aglycoside forms.
- Separate solutions (0.02% in distilled water) were made for genistein, genistin, daidzein, daidzin, and isoflavone concentrate in volumetric flasks. Samples were then placed in a 37° C. water bath for 17 hours, followed by rapid filtration through a 0 2 micron syringe-type filter to remove particulates. Filtered samples were then analyzed for isoflavone concentration by HPLC. Results are tabulated as shown in Table 5
TABLE 5 Differential Solubility of Isoflavone Glycosides vs. Aglycones Isoflavone Genistein Genistin Daidzein Daidzin sample (ppm) (ppm) (ppm) (ppm) Genistein 7 42 Genistin 33.89 Daidzein 3 64 Daidzin 48 51 Isoflavone 0 492 30 075 0.672 37 69 Concentrate - The glycoside forms, genistin and daidzin, are at least 4 57 and 13.32 fold higher in concentration at 37° C. than their corresponding aglycone forms, respectively
- The modifications made to the isoflavones are to remove the carbohydrate attached to the isoflavones moiety. This modification renders the isoflavone less soluble in water. Maintenance of the natural modification, glycosylation, enhances solubility. This fact is shown in the comparative solubility chart of Table 5 This chart shows that the genistin isoflavone is 4 6 times higher and the daidzin isoflavone is 13.3 times higher than the corresponding non-glycosylated form. Higher solubility can lead to better bioavailability to intestinal organisms. The glycosylation does not inhibit absorption in the gut because the intestinal microflora convert the glycone form to the aglycone form before absorption occurs
- Lignans can be readily extracted from flax using this following method.
- 978 g of defatted flax meal (F1) was extracted with 2000 g of 85% ethanol at 40° C. for 10 minutes, forming a slurry. The resulting slurry was filtered and extraction was repeated twice with a total of 6000 g of ethanol.
- The ethanolic fraction was then evaporated under vacuum at 70° C., resulting in an aqueous fraction of 1186 g The aqueous fraction was combined with 1000 g of water and mixed.
- The mixed sample was then ultra-filtered through a 5000 molecular weight cutoff membrane, resulting in a 767 g permeate fraction and a retentate fraction of 1283 g.
- The retentate fraction was freeze-dried, resulting in a 27 84 g sample (F2)
- The 767 g permeate fraction at 50° C. was fed to a 35 ml bed volume, XAD-4 resin column at a rate of 10 ml/min The column effluent was collected and dried, resulting in a 14 8 g sample (F3) XAD-4 is a trademark for an absorbent resin, available from Rohm & Haas.
- The column was then eluted with four bed volumes (140 ml) of 70% ethanol at 50° C. The eluent sample was evaporated under vacuum at 70° C. and dried, resulting in a 1.79 g sample (F4) The four fractions were then analyzed for their lignan content, measured as the concentration by weight of secoisolariciresinol. As Table 6 shows, this extraction method enriches lignan concentration.
TABLE 6 LIGNAN CONCENTRATIONS AS SECOISOLARICIRESINOL FRACTION F1 F2 F3 F4 SECO. CONC. (mg/g) 2.3 1.9 4 8 13.4 PHENOLIC ACID - While the present invention has been disclosed in terms of the preferred embodiment in order to facilitate a better understanding of the invention, it should be appreciated that the invention can be embodied in various ways without departing from the principles of the invention Therefore, the invention should be understood to include all possible embodiments, modifications, and equivalents to the described embodiment which do not depart form the principles of the inventions as set out in the appended claims
Claims (74)
1. A composition from a plant matter in which the composition is enriched in at least two of the phytochemicals selected from the group consisting of isoflavones, lignans, saponins, catechins and phenolic acids
2. The composition of claim 1 which essentially consists of at least 70% by weight phytochemicals selected from the group comprising isoflavones, lignans, saponins, catechins and phenolic acids
3. The composition of claim 1 in which at least one of the selected phytochemicals comprises at least 10% by weight of the composition
4. The composition of claim 1 which essentially consists of at least 80% by weight phytochemicals selected from the group comprising isoflavones, lignans, saponins, catechins and phenolic acids
5. The composition of claim 1 which essentially consists of at least 90% by weight phytochemicals selected from the group comprising isoflavones, lignans, saponins, catechins and phenolic acids.
6. The composition of claim 1 in which the ratio of isoflavones to lignans is selected from the range of about 1000.1 to about 1 50.
7. The composition of claim 1 in which the ratio of isoflavones to saponins is selected from the range of about 1:10 to about 10 1.
8. The composition of claim 1 in which the ratio of isoflavones to phenolic acids is selected from the range of about 100 to 1 to about 1 to 100
9. The composition of claim 1 in which the ratio of lignans to saponins is selected from the range of out 100 to 1 to about 1 to 100
10. The composition of claim 1 in which the ration of lignans to phenolic acids is selected from the range of about 100 to 1 to about 1 to 100
11. The composition of claim 1 in which the ratio of saponins to phenolic acids is selected from the range of about 100 to 1 to about 1 to 100
12. The composition of claim 1 in which the ratio to catechins to phenolic acid is selected form a range of about 100 to 1 to about 1 to 100.
13. The composition of claim 1 in which the isoflavones are present in an amount from approximately 5% to approximately 90% by weight.
14. The composition of claim 1 in which the lignans are present in an amount from about 1% to about 70% by weight.
15. The composition of claim 1 in which the saponins are present in an amount from about 5% to about 70% by weight.
16. The composition of claim 1 in which the phenoilc acids are present in an amount from about 1% to about 70% by weight.
17. The composition of claim 1 in which the isoflavones are selected from the group consisting essentially of genistein, daidzein, glycitein, biochanin A, formononetin, and natural modifications thereof
18. The composition of claim 1 in which the lignans are selected from the group consisting essentially of matairesinol, secoisolariciresinol, lanciresinol, isolariciresinol, nordihydroguaiaretic acid, pinoresionl, olivil, and precursors of enterolactone and enterodiol and natural modifications thereof.
19. The composition of claim 1 in which the saponins are selected from the group consisting essentially of tomatine, soyasapogenols A, B, C, D, E and F, soysapnin, alfalfasaponin, ginsengoside fraction 3 and 4, medicagenic acid. hederagenin, glycyrrhizin digitoning, quillaja saponin, lucernic acid, zahnic acid, and natural modifications of these compounds.
20. The composition of claim 1 in which the phenolic acids are selected from the group consisting essentially or chlorocenic acid, caffeic acid, ferulic acid, gallic acid, sinapic acid, syringic acid, vanillic acid, coumeric acid, cinnamic acid, gentisic acid, salicylic acid, hydroxy benzoic acid and hydroxy phenyl acetic acids and derivatives thereof.
21. The composition of claim 1 in which catechins are selected from the group consisting essentially of catechin, epicatechin, gallocatechin, and epigallocatechin.
22. The composition of claim 1 in which the plant matter is selected from one or more of the group consisting essentially of soy, red clover, kudzu, flax, alfalfa, tea, and cocoa.
23. The composition of claim 1 in which the plant matter is soy.
24. The composition of claim 23 , in which the soy is selected from the group consisting of soybean, soy foods, soy molasses, soy whey, soy protein, and soy flour.
25. A product for oral delivery comprising a composition extracted from plant matter which is enriched in two or more of the phytochemicals selected from the group consisting of isoflavones, lignans, saponins, catechins and phenolic acids.
26. The product of claim 25 wherein the product is selected from the group consisting of tablets, capsules, pills, concentrates, powders, liquids, and added food ingredients.
27. The product of claim 26 comprising tablets comprising
a. the plant matter composition; and
b a filler selected from the group consisting of sorbitol, lactose, cellulose and dicalcium phosphate
28. The product of claim 27 additionally comprising a dietary supplemental nutrient selected from the group consisting of dicalcium phosphate, magnesium stearate, calcium citrate, calcium malate, other calcium sources, vitamins and minerals.
29. The oral delivery product of claim 27 wherein the product comprises between about 15% and about 25% by weight of the composition and between about 65% and about 85% by weight of the filler.
30. The product of claim 28 wherein the product comprises
a. between about 15% and about 25% by weight of the composition,
b between about 60% and about 84% by weight of the filler; and
c. between about 1% and about 25% by weight of the dietary supplemental nutrient.
31. The oral delivery product of claim 26 comprising capsules including
a. a predetermined dosage of the plant matter composition; and
b. a gelatin capsule.
32. The oral delivery product of claim 26 wherein the plant matter composition is extracted from plants selected from the group consisting of soy, red clover, kudzu, flax, alfalfa, tea, and cocoa.
33. The oral delivery product of claim 23 wherein the product comprises between about 10 milligrams and about 2000 milligrams of the plant matter composition
34. A method of treating a disease selected from the group consisting of breast cancer, skin cancer, and colon cancer, said method comprising the step of administering to the subject a therapeutically effective amount of a composition extracted from plant matter which is enriched in at least one of the phytochemicals selected from the group of isoflavones, lignans, saponins, catechins and phenolic acids
35. The method of claim 34 wherein the treatment is for breast cancer
36. The method of claim 34 wherein the treatment is for skin cancer
37. The method of claim 34 wherein the treatment is for colon cancer.
38. A method of treating at least one disease selected from the group consisting of urinary cancer, bladder cancer, and prostate cancer in a subject, said method comprising the step of administering to the subject a therapeutically elective amount of a composition extracted from plant matter which is enriched in at least one of the phytochemicals selected from the group of isoflavones, lignans, saponins, catechins and phenolic acids.
39. The method of claim 38 wherein the treatment is for urinary cancer
40. The method of claim 38 wherein the treatment is for bladder cancer
41. The method of claim 38 wherein the treatment is for prostate cancer
42. A method of treating one disorder selected from the group consisting of migraine headache and dementia in a subject, said method comprising the step of administering to the subject a therapeutically effective amount or a composition extracted from plant matter which is enriched in at least one of the phytochemicals selected from the group of isoflavones, lignans, saponins, catechins and phenolic acids.
43. The method of claim 42 wherein the treatment is for migraine headache.
44. The method of claim 42 wherein the treatment is for dementia.
45. A method of reducing alcohol dependency in a subject said method comprising the step of administering to the subject a therapeutically effective amount of a composition extracted from plant matter which is enriched in at least one of the phytochemicals selected from the group of isoflavones, lignans, saponins, catechins and phenolic acids.
46. A method of reducing bloodstream cholesterol, reducing the risk of coronary heart disease, or modulating blood lipid profiles in a subject, said method comprising the step of administering to the subject a therapeutically effective amount of a composition extracted from plant matter Which is enriched in at least one of the phytochemicals selected from the group of isoflavones, lignans, saponins, catechins, and phenolic acids.
47. The method of claim 46 wherein bloodstream cholesterol is reduced.
48. The method of claim 46 wherein the risk of coronary heart disease is reduced.
49. The method of claim 46 wherein blood lipid profiles are modulated
50. A method of reducing or preventing hot flashes, osteoporosis, sleep disorders, vaginal dryness or premenstrual syndrome in a subject, said method comprising the step of administering to the subject a therapeutically effective amount of a composition extracted from plant matter which is enriched in at least one of the phytochemicals selected from the group of isoflavones, lignans, saponins, catechins, and phenolic acids.
51. The method of claim 50 wherein hot flashes are treated or prevented.
52. The method of claim 51 wherein osteoporosis is treated or prevented.
53. The method of claim 51 wherein premenstrual syndrome is treated or prevented.
54. The method of claim 51 wherein sleep disorders is treated or prevented.
55. The method of claim 51 wherein vaginal dryness is treated or prevented.
56. The composition of claim 1 in which the plant matter is flax.
57. The composition of claim 56 which consists of at least about 1% by weight lignans
58. The composition of claim 56 which consists of at least about 50%,10 by weight lignans.
59. The composition of claim 1 in which the selected phytochemicals are in a substantially native form.
60. The composition of claim 1 in which the isoflavones are in a substantially glycosylated form.
61. The composition of claim 1 which is added as a supplement to a food.
62. The composition of claim 1 which is consumed as a dietary supplement.
63. The composition of claim 1 in which the plant matter is tea.
64. The composition of claim 1 in which the plant matter is cocoa
65. A composition made by the process comprising the steps of:
a. extracting a defatted material from a group of vegetable matter consisting of protein, meal, whey, molasses, solubles and germs in a solution including an alcoholic solvent to produce a slurry;
b filtering the slurry of step (a) to produce an alcoholic fraction,
c. evaporating said alcoholic fraction of step (b) to produce an aqueous fraction;
d. ultrafiltering said aqueous fraction of step (c),
e. feeding a permeate of step (d) through a resin column; and
f. collecting an effluent from said column after said wash.
66. The composition of claim 65 and the further step of preparing said effluent of step (f) into a form which is suitable for administering orally, said form being taken from a group consisting of a concentrate, dried powder, capsule, pellet, and pill.
67. The composition of claim 66 wherein said dried powder is a bulk volume of material for further manufacture to provide individual dose sizes for said oral administration.
68. The composition of claim 65 wherein said vegetable matter is selected from a group consisting of soy, red clover, kudzu, flax, alfalfa, tea, and cocoa.
69. The composition of claim 65 wherein said vegetable matter is soy.
70. The composition of claim 65 wherein step (c) includes a step of diluting said aqueous fraction.
71. The composition of claim 65 and the added step of fractionating said effluent to select at least one of the group consisting essentially of isoflavones, lignans, saponins, catechins, and phenolic acid.
72. The composition of claim 65 and the added step of fractionating said effluent to select isoflavones.
73. The composition of claim 65 wherein the solution of step (a) is about 70% ethanol and the extraction is carried out at about 40° C.
74. The composition of claim 65 where the evaporation of step (c) is carried out under vacuum at about 70° C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/136,103 US20020168433A1 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of alcoholism |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/614,545 US5702752A (en) | 1996-03-13 | 1996-03-13 | Production of isoflavone enriched fractions from soy protein extracts |
US08/868,629 US5792503A (en) | 1996-03-13 | 1997-06-04 | Production of isoflavone enriched fractions from soy protein extracts |
US6054997P | 1997-10-02 | 1997-10-02 | |
US09/035,588 US6033714A (en) | 1996-03-13 | 1998-03-05 | Process for production of isoflavone fractions from soy |
US09/162,038 US6261565B1 (en) | 1996-03-13 | 1998-09-28 | Method of preparing and using isoflavones |
US09/615,152 US6399072B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of alcoholism |
US10/136,103 US20020168433A1 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of alcoholism |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/615,152 Division US6399072B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of alcoholism |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020168433A1 true US20020168433A1 (en) | 2002-11-14 |
Family
ID=26740043
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/162,038 Expired - Lifetime US6261565B1 (en) | 1996-03-13 | 1998-09-28 | Method of preparing and using isoflavones |
US09/616,150 Expired - Fee Related US6395279B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of cancer |
US09/615,152 Expired - Fee Related US6399072B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of alcoholism |
US09/615,239 Expired - Fee Related US6391308B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of blood related illnesses |
US09/615,240 Expired - Lifetime US6391309B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of female symptoms |
US10/136,150 Expired - Lifetime US6518319B1 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms |
US10/136,103 Abandoned US20020168433A1 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of alcoholism |
US10/137,490 Expired - Fee Related US6900240B2 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer |
US10/136,079 Abandoned US20030064938A1 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of cardiovascular conditions |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/162,038 Expired - Lifetime US6261565B1 (en) | 1996-03-13 | 1998-09-28 | Method of preparing and using isoflavones |
US09/616,150 Expired - Fee Related US6395279B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of cancer |
US09/615,152 Expired - Fee Related US6399072B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of alcoholism |
US09/615,239 Expired - Fee Related US6391308B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of blood related illnesses |
US09/615,240 Expired - Lifetime US6391309B1 (en) | 1996-03-13 | 2000-07-13 | Method of preparing and using isoflavones for the treatment of female symptoms |
US10/136,150 Expired - Lifetime US6518319B1 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/137,490 Expired - Fee Related US6900240B2 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer |
US10/136,079 Abandoned US20030064938A1 (en) | 1996-03-13 | 2002-05-01 | Method of preparing and using compositions extracted from vegetable matter for the treatment of cardiovascular conditions |
Country Status (16)
Country | Link |
---|---|
US (9) | US6261565B1 (en) |
EP (2) | EP0906761B1 (en) |
JP (1) | JPH11221048A (en) |
KR (2) | KR19990066785A (en) |
AT (2) | ATE270894T1 (en) |
AU (1) | AU748832B2 (en) |
CA (1) | CA2249501C (en) |
DE (1) | DE69825003T2 (en) |
DK (1) | DK0906761T3 (en) |
ES (2) | ES2224337T3 (en) |
HK (1) | HK1016879A1 (en) |
IL (1) | IL126433A (en) |
NO (1) | NO318696B1 (en) |
NZ (1) | NZ332131A (en) |
PT (1) | PT906761E (en) |
TW (1) | TWI241893B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030064938A1 (en) * | 1996-03-13 | 2003-04-03 | Mark Empie | Method of preparing and using compositions extracted from vegetable matter for the treatment of cardiovascular conditions |
US20030180436A1 (en) * | 2002-03-22 | 2003-09-25 | Pizzey Glenn Roy | High lignan flaxseed product and product by process |
US20060210691A1 (en) * | 2005-03-15 | 2006-09-21 | Pizzey Glenn R | Methods of increasing flaxseed hull recovery and resultant flax products |
US20080260924A1 (en) * | 2007-04-20 | 2008-10-23 | Liang-Rong Chen | Composition Comprising Five Kinds of Processed Fruit or Vegetables |
WO2010075418A2 (en) * | 2008-12-23 | 2010-07-01 | The Administrators Of The Tulane Educational Fund | Glyceollins suppress androgen-responsive prostate cancer |
Families Citing this family (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2136233C (en) * | 1992-05-19 | 2004-03-30 | Graham Edmund Kelly | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
US5554645A (en) | 1994-10-03 | 1996-09-10 | Mars, Incorporated | Antineoplastic cocoa extracts and methods for making and using the same |
US6391310B1 (en) * | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of neurological symptoms |
US5821361A (en) * | 1996-06-11 | 1998-10-13 | Protein Technologies International, Inc. | Recovery of isoflavones from soy molasses |
AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
US7968140B2 (en) | 1997-09-08 | 2011-06-28 | Mars, Incorporated | Chocolates and chocolate liquor having an enhanced polyphenol content |
US6558713B2 (en) | 1996-09-06 | 2003-05-06 | Mars, Incorporated | Health of a mammal by administering a composition containing at least one cocoa polyphenol ingredient |
US6998418B1 (en) | 1996-11-05 | 2006-02-14 | Gp Medical, Inc. | Acellular biological material chemically treated with genipin |
US6146668A (en) | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
US6340703B1 (en) * | 1997-05-01 | 2002-01-22 | Novogen, Inc. | Treatment or prevention of osteoporosis |
AU1289899A (en) * | 1997-10-31 | 1999-05-24 | Arch Development Corporation | Methods and compositions for regulation of 5-alpha reductase activity |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
AUPP260798A0 (en) * | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
CA2333556A1 (en) * | 1998-05-27 | 1999-12-02 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of migraine headaches |
WO1999066915A2 (en) * | 1998-06-23 | 1999-12-29 | Southern Illinois University At Carbondale | Therapeutic applications of estrogenic carboxylic acids |
JP2000095792A (en) * | 1998-09-21 | 2000-04-04 | Showa Sangyo Co Ltd | Acquisition of isoflavone composition comprising genistin |
ATE301460T1 (en) * | 1999-04-13 | 2005-08-15 | Scigenic Co Ltd | PREPARATION FOR THE PROPHYLAXIS OR TREATMENT OF DEMENTIA CONTAINING A HYDROXYCINNAMIC ACID DERIVATIVE OR AN EXTRACT OF A PLANT OF THE GENUS ANGELICA CONTAINING SUCH ACID. |
US6592910B1 (en) * | 1999-04-20 | 2003-07-15 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
AUPQ008399A0 (en) * | 1999-04-28 | 1999-05-27 | Novogen Research Pty Ltd | Cariovascular applications |
US20040072765A1 (en) * | 1999-04-28 | 2004-04-15 | Novogen Research Pty Ltd. | Cardiovascular and bone treatment using isoflavones |
WO2000067749A1 (en) * | 1999-05-05 | 2000-11-16 | Unilever N.V. | Food product |
WO2000067750A1 (en) * | 1999-05-05 | 2000-11-16 | Unilever N.V. | Food product |
US6641847B1 (en) | 1999-06-01 | 2003-11-04 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
FR2794616B1 (en) * | 1999-06-11 | 2001-09-07 | Tekory S A R L | NATURAL FOOD SUPPLEMENT FOR DECREASING THE RATE OF PLASMA CHOLESTEROL AND PROCESS FOR PREPARING THE SAME |
AUPQ266199A0 (en) * | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
US20090233999A1 (en) * | 1999-09-06 | 2009-09-17 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
ATE388718T1 (en) | 1999-09-30 | 2008-03-15 | Factors R & D Technologies Ltd | ECHINACEA COMPOSITION AND METHOD FOR PREPARATION |
JP4413464B2 (en) * | 1999-12-17 | 2010-02-10 | 光則 小野 | Water-soluble bean-based extract |
US7182972B2 (en) | 1999-12-17 | 2007-02-27 | Quercegen Pharma, Llc | Water-soluble bean-based extracts |
AU2005220186B2 (en) * | 1999-12-17 | 2008-08-28 | Lan Bo Chen | Water soluble bean-based extracts |
AUPQ520300A0 (en) * | 2000-01-21 | 2000-02-17 | Novogen Research Pty Ltd | Food product and process |
CA2405348A1 (en) * | 2000-04-13 | 2001-11-01 | Ocean Spray Cranberries, Inc. | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor |
AU2001256855A1 (en) * | 2000-05-08 | 2001-11-20 | N.V. Nutricia | Preparation for the prevention and treatment of ocular disorders |
KR100432234B1 (en) * | 2000-05-12 | 2004-05-20 | 솔레 엘엘씨 | Process for separating and recovering protein and isoflavones from a plant material |
US6627232B1 (en) | 2000-06-09 | 2003-09-30 | Mars Incorporated | Method for extracting cocoa procyanidins |
US7438936B2 (en) | 2000-06-12 | 2008-10-21 | Access Business Group International Llc | Dietary supplement and related method |
US6989161B2 (en) | 2000-06-12 | 2006-01-24 | Access Business Group International Llc | Phytonutrient nutritional supplement |
US7416749B2 (en) | 2000-06-12 | 2008-08-26 | Access Business Group International Llc | Dietary supplement and related method |
US7939115B2 (en) | 2000-06-12 | 2011-05-10 | Access Business Group International Llc | Dietary supplement and related method |
JP2002051732A (en) * | 2000-06-12 | 2002-02-19 | Access Business Group Llc | Composition and method for correcting deficiency disease of vegetable chemical substance by diet |
JP3548102B2 (en) * | 2000-08-07 | 2004-07-28 | 花王株式会社 | Antihypertensive agent |
FR2812873B1 (en) | 2000-08-11 | 2003-08-01 | Barry Callebaut France | PROCESS FOR PRODUCING POLYPHENOLS FROM COCOA BEANS |
CA2358321A1 (en) * | 2000-09-29 | 2002-03-29 | Kraft Foods Holdings, Inc. | Method and composition which inhibits the oxidation of omega-3- and omega-6 polyunsaturated lipids |
JP4858889B2 (en) * | 2000-10-20 | 2012-01-18 | 有限会社大長企画 | Nutrient, digestive |
AU2001235969A1 (en) * | 2000-10-23 | 2002-05-06 | Council Of Scientific And Industrial Research | Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara |
US7429399B2 (en) * | 2001-06-18 | 2008-09-30 | Solae, Llc | Modified oilseed material |
US20040219281A1 (en) * | 2000-11-21 | 2004-11-04 | Cargill, Incorporated | Modified oilseed material |
US6632459B2 (en) | 2000-12-11 | 2003-10-14 | Nutricia N.V. | Chlorogenic acid and an analog thereof for immune system stimulation |
FR2818096B1 (en) * | 2000-12-14 | 2004-05-07 | Daniel Chajuss | PHYTOCHEMICAL COMPOSITION OF SOYBEANS |
JP4880816B2 (en) * | 2000-12-15 | 2012-02-22 | 株式会社ヤクルト本社 | Skin anti-aging agent |
US20020114795A1 (en) * | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
US20060034954A1 (en) * | 2001-02-02 | 2006-02-16 | Bland Jeffrey S | Medical composition for balancing bodily processes |
US20030190381A1 (en) * | 2001-02-02 | 2003-10-09 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
US20070059378A1 (en) * | 2001-02-02 | 2007-03-15 | Metagenics, Inc. | Medical composition for balancing bodily processes |
US20040220118A1 (en) * | 2001-02-02 | 2004-11-04 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
US20050119301A1 (en) * | 2001-03-16 | 2005-06-02 | Alan Husband | Treatment of restenosis |
US6767565B2 (en) * | 2001-03-22 | 2004-07-27 | Archer Daniels Midland Company | Process for obtaining lignan |
EP1377182B1 (en) * | 2001-04-04 | 2006-08-16 | Unilever N.V. | Use of lignans in foods |
WO2003010116A2 (en) * | 2001-07-24 | 2003-02-06 | Cargill, Incorporated | Process for isolating phenolic compounds |
US6592911B2 (en) * | 2001-07-27 | 2003-07-15 | Council Of Scientific And Industrial Research | (−)-Olivil as antioxidant which is obtained from a new natural source namely Stereospermum personatum |
US6489514B1 (en) * | 2001-07-27 | 2002-12-03 | Council Of Scientific And Industrial Research | (-)-Secoisolariciresinol as an antioxidant obtained from a new natural source namely stereospermum personatum |
US7338971B2 (en) * | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
US6586018B1 (en) * | 2001-08-31 | 2003-07-01 | Sabina Fasano | Herbal composition |
KR100460103B1 (en) * | 2001-10-18 | 2004-12-04 | 롯데제과주식회사 | Drug with inhibitor effects on digestive system carcinogenesis containing cacao bean and husk fraction extract |
US7008666B2 (en) | 2001-11-26 | 2006-03-07 | Hormos Nutraceutical Oy Ltd. | Method of inhibiting overactivity of phagocytes or lymphocytes in an individual |
CN100444837C (en) * | 2001-12-05 | 2008-12-24 | 科学与工业研究委员会 | Novel herbal chemical composition for treatment of cancer |
JP2012149096A (en) * | 2001-12-18 | 2012-08-09 | Daicho Kikaku:Kk | Anti-inflammatory preparation |
JP5384777B2 (en) * | 2001-12-18 | 2014-01-08 | 有限会社大長企画 | Strong muscle agent, anti-inflammatory agent |
US20030144216A1 (en) * | 2002-01-25 | 2003-07-31 | Mikko Unkila | Method for prevention of diseases in coeliac patients |
EP1472206A1 (en) * | 2002-02-05 | 2004-11-03 | Hormos Medical Corporation | Lignan derivatives |
EP1808172A3 (en) * | 2002-03-06 | 2010-05-26 | Activephyto Technologies Limited | Botanical extract compositions and methods of use |
ATE361746T1 (en) * | 2002-03-06 | 2007-06-15 | Medical Res And Education Trus | BOTANICAL EXTRACT WITH ANTI-CANCER ACTIVITY CONTAINING ISOLIQUIRITIGENIN |
JP4684556B2 (en) * | 2002-03-11 | 2011-05-18 | サントリーホールディングス株式会社 | Method for producing SDG and its blended food and drink |
US7514107B2 (en) * | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
WO2003082888A1 (en) * | 2002-03-26 | 2003-10-09 | Wiley Organics, Inc. | Process for isolating genisting from mixtures of soy isoflavones |
TWI331032B (en) * | 2002-05-01 | 2010-10-01 | Hayashibara Biochem Lab | |
EP1503632A1 (en) * | 2002-05-02 | 2005-02-09 | Volker Kuellmer | Coated, agglomerated phytochemicals |
KR100479405B1 (en) * | 2002-05-24 | 2005-03-30 | 주식회사 싸이제닉 | Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease |
US7214394B2 (en) * | 2002-05-31 | 2007-05-08 | Archer-Daniels-Midland Company | Policosanol compositions, extraction from novel sources, and uses thereof |
WO2003103682A1 (en) * | 2002-06-11 | 2003-12-18 | Panagin Pharmaceuticals Inc. | Compositions for cancer therapy saponins or sapogenins |
DK1450786T3 (en) * | 2002-06-29 | 2006-04-18 | Aquanova Ger Solubilisate Tech | Isoflavone concentrates and process for their preparation |
US20040009872A1 (en) * | 2002-07-15 | 2004-01-15 | Gordon Cohen | Method using solvents for improved microporous polymeric adsorbents |
WO2004009521A1 (en) * | 2002-07-18 | 2004-01-29 | Takara Bio Inc. | Remedy |
US20060035964A1 (en) * | 2002-07-24 | 2006-02-16 | Shigetoshi Kadota | Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan |
US7396855B2 (en) | 2002-07-24 | 2008-07-08 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
WO2004010965A1 (en) * | 2002-07-25 | 2004-02-05 | L'oreal | Use of lignans for prevening or treating the sings of ageing of the skin |
FR2842731B1 (en) * | 2002-07-25 | 2005-12-30 | Oreal | USE OF LIGNANS TO PREVENT OR TREAT THE SIGNS OF SKIN AGING |
FR2842732B1 (en) * | 2002-07-25 | 2005-06-24 | Oreal | COSMETIC USE OF LIGNANS |
WO2004012697A1 (en) * | 2002-07-25 | 2004-02-12 | L'oréal | Cosmetic use of lignans |
WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
US20040131749A1 (en) * | 2002-08-29 | 2004-07-08 | Archer-Daniels-Midland Company | Phytochemicals from edible bean process streams |
FI114917B (en) * | 2002-08-29 | 2005-01-31 | Hormos Nutraceutical Oy Ltd | Lignaanikomplekseja |
US20060251750A1 (en) * | 2002-09-30 | 2006-11-09 | Tabor Aaron T | Soy formulations and their use in skin care |
KR20040038481A (en) * | 2002-11-01 | 2004-05-08 | 주식회사 렉스진바이오텍 | Health aid food containing isoflavone-containing extract from natural plant |
US20040097432A1 (en) * | 2002-11-04 | 2004-05-20 | Access Business Group International Llc. | Method of reducing cholesterol |
JP2004171733A (en) * | 2002-11-06 | 2004-06-17 | Alps Electric Co Ltd | Magnetic head, magnetic tape device including the same and method for producing the magnetic head |
WO2004043945A1 (en) * | 2002-11-12 | 2004-05-27 | Wiley Organics, Inc. | Method for purifying and separating soy isoflavones |
US20040254357A1 (en) * | 2002-12-19 | 2004-12-16 | Zaloga Gary P. | Fatty acid phenolic conjugates |
ITMI20022723A1 (en) * | 2002-12-20 | 2004-06-21 | Marfarma S R L Ora Marfarma Holding Spa | COMPOSITIONS FOR THE TREATMENT OF POST-MENOPAUSE SYNDROME. |
US7560131B2 (en) * | 2002-12-24 | 2009-07-14 | Fuji Oil Company, Limited | High solubility composition with high isoflavone concentration and process of producing same |
DE10300187B4 (en) * | 2003-01-08 | 2007-03-29 | Cognis Ip Management Gmbh | Chewing gum composition with herbal ingredients |
EP1471070A1 (en) * | 2003-04-22 | 2004-10-27 | Royal Schouten Group N.V. | Method for recovering a secondary plant metabolite |
NZ526098A (en) * | 2003-05-23 | 2005-10-28 | Enzo Nutraceuticals Ltd | Use of a plant extract containing flavonoids rich in proanthocyanidins for the prevention or treatment of migraine |
US7025998B2 (en) | 2003-05-30 | 2006-04-11 | Rotta Research Laboratorium S.P.A. | Phytoestrogens and probiotic for women's health |
US7718813B2 (en) | 2003-08-15 | 2010-05-18 | Nature Pure Labs Sw, Inc. | Hydrolysis and purification of active plant compounds suitable for topical application |
KR100751071B1 (en) * | 2003-10-10 | 2007-08-21 | 에스케이케미칼주식회사 | Triterpene compounds which are effective on improvement of brain function |
US20050202139A1 (en) * | 2003-11-05 | 2005-09-15 | Corbin David R. | Recovery of isoflavones from aqueous mixtures using zeolites or molecular sieves |
US7618671B2 (en) * | 2003-11-05 | 2009-11-17 | E.I. Du Pont De Nemours And Company | Recovery of isoflavones and removal of oligosaccharides from aqueous mixtures using zeolites |
US20050118290A1 (en) * | 2003-12-02 | 2005-06-02 | University Of Singapore | Compositions and method for treatment of steroid/nuclear receptor-mediated diseases |
CN1893939B (en) * | 2003-12-26 | 2011-12-28 | 农工大Tlo株式会社 | Composition for preventing and treating hepatoma |
US7557154B2 (en) * | 2004-12-23 | 2009-07-07 | Sabic Innovative Plastics Ip B.V. | Polymer compositions, method of manufacture, and articles formed therefrom |
KR100739280B1 (en) * | 2004-02-03 | 2007-07-12 | 가부시끼가이샤 고또스기 | Therapeutic/Preventive Agent for Osteoporosis Containing As Component Isotaxiresinol Derived from Taxus Yunnanensis |
US20050214367A1 (en) * | 2004-03-22 | 2005-09-29 | Volker Kuellmer | Processes for making coated phytochemicals and tocopherols and products formed therefrom |
US20050220978A1 (en) * | 2004-03-31 | 2005-10-06 | Cargill, Incorporated | Dispersible protein composition |
US8663679B2 (en) | 2004-04-29 | 2014-03-04 | Abbott Laboratories | Compositions for improving breast health in women |
US8377484B1 (en) | 2004-05-06 | 2013-02-19 | Maria V. Tsiper | Tumor encapsulation for prevention and treatment of metastatic cancer disease |
CN1305869C (en) * | 2004-05-21 | 2007-03-21 | 薛存宽 | Tech. for preparing isoflavone of red clover from red clover |
GB2414393B (en) * | 2004-05-24 | 2008-06-11 | Natraceutical Sa | Process for producing cocoa polyphenol concentrate |
AU2005249147B2 (en) | 2004-06-04 | 2011-03-24 | Poly Gain Pte Ltd | Natural sweetener |
US20050288405A1 (en) * | 2004-06-29 | 2005-12-29 | General Electric Company | Copolymers containing diimide moieties and blends thereof |
US20060004151A1 (en) * | 2004-06-30 | 2006-01-05 | General Electric Company | Copolymers containing indan moieties and blends thereof |
US20060009506A1 (en) * | 2004-07-09 | 2006-01-12 | Odyssey Thera, Inc. | Drugs for the treatment of neoplastic disorders |
US7435431B2 (en) * | 2004-07-28 | 2008-10-14 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
MX2007001128A (en) * | 2004-07-28 | 2007-04-17 | Abbott Lab | Nutritional compositions and methods for treating or preventing osteoporosis. |
US7601370B2 (en) * | 2004-07-28 | 2009-10-13 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
US20060045927A1 (en) * | 2004-08-25 | 2006-03-02 | Dajian Yang | Herbal formulations for modulating blood lipids |
EP1640001A1 (en) * | 2004-09-24 | 2006-03-29 | New Pharma Investments Holding | Composition against cardiovascular diseases |
US20060088617A1 (en) * | 2004-10-23 | 2006-04-27 | Mccurry James M | Chocolate composition and method for benefiting the cardiovascular system |
US20150005360A1 (en) | 2004-10-25 | 2015-01-01 | Nse Products, Inc. | Phytoestrogen compositions and associated methods |
DE102004060314A1 (en) * | 2004-12-08 | 2006-08-31 | Beiersdorf Ag | Active ingredient combinations of one or more isoflavonoids and carnitine and / or one or more acyl-carnitines |
AU2005323934A1 (en) * | 2005-01-10 | 2006-07-13 | Hormos Medical Ltd | The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency |
EP1864644B1 (en) * | 2005-03-25 | 2017-02-01 | Seiren Co., Ltd. | Use of sericin for improvement in feeling of denture upon use |
AU2006232344A1 (en) * | 2005-04-04 | 2006-10-12 | Archer-Daniels-Midland Company | Lignan-containing compositions |
US7563464B1 (en) * | 2005-04-22 | 2009-07-21 | Bruce Eric Hudkins | Treatment of mucosal membranes utilizing phytoestrogen |
EP2450084B1 (en) | 2005-06-03 | 2014-02-19 | Horizon Science Pty Ltd | Substances having body mass redistribution properties |
WO2006134609A2 (en) * | 2005-06-16 | 2006-12-21 | Mmi Corporation | Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof |
JP2006347978A (en) * | 2005-06-17 | 2006-12-28 | Nippon Flour Mills Co Ltd | Anti-obesity agent, and food and pet food containing the same |
US7276257B2 (en) * | 2005-07-22 | 2007-10-02 | The Hong Kong University Of Science And Technology | Schisandrin B preparation |
MXPA05008573A (en) * | 2005-08-12 | 2007-02-12 | Leopoldo Espinosa Abdala | Isoflavones composition for treating menopause physiological symptoms and disorders. |
US7491414B2 (en) * | 2005-10-12 | 2009-02-17 | Gaia Herbs, Inc. | Anti-inflammatory substances extracted from Echinacea |
KR100715631B1 (en) * | 2005-12-29 | 2007-05-09 | 대한민국 | Production method of isoflavone enforced eggs |
CA2659272C (en) | 2006-07-28 | 2015-06-16 | Bioriginal Food & Science Corporation | Fat containing composition |
US20090263349A1 (en) * | 2006-08-03 | 2009-10-22 | Michael John Story | Methods and compositions for inhibiting angiogenesis |
JP2008044872A (en) * | 2006-08-11 | 2008-02-28 | Nippon Supplement Kk | Health food containing isolariciresinol, blood cholesterol-reducing agent and body fat-reducing agent |
US9364016B2 (en) | 2006-09-19 | 2016-06-14 | The Product Makers (Australia) Pty Ltd | Extracts derived from sugar cane and a process for their manufacture |
US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
KR100789169B1 (en) * | 2007-01-25 | 2008-01-16 | 네이쳐스메디신 주식회사 | Method for processing food containing flaxseed |
KR100844376B1 (en) * | 2007-02-07 | 2008-07-07 | 한국화학연구원 | Composition for preventing or treating osteoporosis comprising an extract of myristica fragrans or active compounds isolated therefrom |
JP5414192B2 (en) * | 2007-03-29 | 2014-02-12 | 江崎グリコ株式会社 | Circadian rhythm adjustment composition |
US9114114B2 (en) | 2007-06-21 | 2015-08-25 | Mars, Inc. | Edible products having a high cocoa polyphenol content and improved flavor and the milled cocoa extracts used therein |
US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
US8053004B2 (en) * | 2007-10-08 | 2011-11-08 | Starmaker Products, Llc | Ointment for topical treatment of hot flashes and method of use |
US20090176871A1 (en) * | 2008-01-07 | 2009-07-09 | Schoenwetter Phillip E | Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones |
GB0801119D0 (en) | 2008-01-22 | 2008-02-27 | Barry Callebaut Ag | Composition |
EP2133080A1 (en) * | 2008-06-13 | 2009-12-16 | Haelan Schweiz GmbH | Compounds containing equol |
US9433595B2 (en) * | 2008-12-26 | 2016-09-06 | Natural Endotech Co., Ltd. | Phytoestrogenic compositions for preventing or treating symptoms associated with menopause |
RU2496488C2 (en) | 2009-04-28 | 2013-10-27 | Вм. Ригли Дж. Компани | Oral compositions for skin improvement |
KR101876471B1 (en) | 2009-05-26 | 2018-07-16 | (주)아모레퍼시픽 | Compositions Comprising Bean Extracts for Improving Blood Circulation and Vascular Health |
AU2011329054B2 (en) | 2010-11-15 | 2015-05-28 | Zimmer Orthobiologics, Inc. | Bone void fillers |
IT1405432B1 (en) * | 2010-12-16 | 2014-01-10 | Funcional Food Res S R L | FUNCTIONAL FOOD PREPARATION AND RELATIVE USE. |
KR101266889B1 (en) * | 2011-01-13 | 2013-05-24 | 주식회사 보타메디 | Functional food compositions having the recovery effect of blood composition and function |
KR101229878B1 (en) * | 2011-02-07 | 2013-02-18 | 대한민국 | Composition for the treatment of alcoholism comprising a rice or its extracts |
AU2012214104C1 (en) | 2011-02-08 | 2017-08-03 | Poly Gain Pte Ltd | Sugar extracts |
US20160038555A1 (en) | 2011-03-31 | 2016-02-11 | Kang Yell Choi | Composition Containing Extracts of the Fruit of Hovenia Dulcis THUNB as an Active Ingredient for Preventing and Treating Bone Diseases |
KR101428512B1 (en) * | 2012-03-09 | 2014-08-12 | 연세대학교 산학협력단 | A pharmaceutical composition for treating and preventing bonedisease containing methyl vanillate |
US9433583B2 (en) | 2011-04-22 | 2016-09-06 | Frank J. Farrell | Colon vitamin |
WO2014032100A1 (en) | 2012-08-28 | 2014-03-06 | Phytolin Pty Ltd | Extraction method |
RU2510268C1 (en) * | 2012-11-14 | 2014-03-27 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс" | Agent for treating oestrogen-dependent cancer |
MX370090B (en) | 2013-02-01 | 2019-10-25 | Centro De Investig En Alimentacion Y Desarrollo A C | Method and system for the integral treatment of wastewater from the maize industry. |
EP3035949B1 (en) | 2013-08-16 | 2023-10-04 | Poly Gain Pte Ltd | Sugar cane derived extracts and uses |
ES2914673T3 (en) * | 2014-06-02 | 2022-06-15 | Thomas Nadackal Thomas | Water enriched with phytochemicals |
WO2017191886A1 (en) * | 2016-05-04 | 2017-11-09 | Phyto Corporation | Functionally reinforced desalted nutritional compositions from halophytes and preparation method thereof |
CN106478763A (en) * | 2016-09-27 | 2017-03-08 | 中国药科大学 | New estrogenic associated receptor alpha inhibitor and its medical usage |
TWI612899B (en) * | 2017-04-27 | 2018-02-01 | 行政院農業委員會農業藥物毒物試驗所 | Camellia seed extract and biopesticides with the same |
CN111683671A (en) | 2017-10-06 | 2020-09-18 | 嘉吉公司 | Method for preparing mate tea extract composition |
JP2022527518A (en) | 2019-04-06 | 2022-06-02 | カーギル インコーポレイテッド | Sensory modifier |
WO2021011788A1 (en) * | 2019-07-16 | 2021-01-21 | Advanced Female Technologies Llc | Chewing gum compositions for the treatment of menopausal symptoms |
TWI749435B (en) * | 2019-09-10 | 2021-12-11 | 大江生醫股份有限公司 | Use of compounds for enhancing expression of genes involved in cholesterol metabolism |
RU2747147C1 (en) * | 2020-06-22 | 2021-04-28 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Pharmaceutical composition exhibiting cytotoxicity towards human colon carcinoma cells |
WO2024071464A1 (en) * | 2022-09-27 | 2024-04-04 | (주)바이오솔릭스 | Anticancer composition comprising maleate metal salt |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808574A (en) * | 1986-12-03 | 1989-02-28 | Nauchno-Issledovatelsky Institut Sadovodstva | Composition inhibiting pathological addiction to alcohol |
US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
US5547671A (en) * | 1995-09-20 | 1996-08-20 | Duthinh; Phu | Anti-intoxication composition |
US5837256A (en) * | 1995-12-21 | 1998-11-17 | Clark; William F. | Method for treatment of Lupus nephritis |
US6399072B1 (en) * | 1996-03-13 | 2002-06-04 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of alcoholism |
US20030180404A1 (en) * | 1999-04-20 | 2003-09-25 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB831306A (en) | 1955-01-13 | 1960-03-30 | British Soya Products Ltd | Improvements in processes for the production of baker's dough |
BE616786A (en) | 1961-04-26 | 1962-08-16 | Spofa Vereinigte Pharma Werke | Process for preparing a substance effective against inflammation |
US3391001A (en) | 1965-02-26 | 1968-07-02 | Griffith Laboratories | Production of flavorful protein hydrolysate |
US3870805A (en) | 1970-11-04 | 1975-03-11 | Staley Mfg Co A E | Process for preparing texturized protein compositions and the resulting product |
US3780182A (en) | 1971-01-18 | 1973-12-18 | Kraftco Corp | Method for imparting cheese-like flavor to proteinaceous materials |
GB1446965A (en) | 1974-02-14 | 1976-08-18 | Agricultural Vegetable Prod | Preparation of food products |
JPS5129280A (en) | 1974-08-12 | 1976-03-12 | Kikkoman Shoyu Co Ltd | Daizuno kakoshorihoho |
GB1575004A (en) * | 1976-03-23 | 1980-09-17 | Iverni Della Beffa Spa | Pharmacologically active polyphenolic substances |
US4264509A (en) | 1977-06-08 | 1981-04-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
US4157984A (en) * | 1977-06-08 | 1979-06-12 | Z-L Limited | Antioxidants, antioxidant compositions and methods of preparing and using same |
DE2900304C3 (en) | 1979-01-05 | 1981-11-05 | Dr. H.Schmittmann Gmbh, 5620 Velbert | Saponin extract product and process for its manufacture |
US4232122A (en) * | 1979-01-17 | 1980-11-04 | Z-L Limited Partnership | Antioxidants, antioxidant compositions and methods of preparing and using same |
US4366248A (en) | 1979-04-11 | 1982-12-28 | Z-L Limited Partnership | Fermentation method of preparing antioxidants |
US4390559A (en) | 1979-04-11 | 1983-06-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
US4366082A (en) | 1979-04-11 | 1982-12-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
DE3040246C2 (en) | 1979-10-29 | 1985-01-10 | Osaka Chemical Laboratory Co., Ltd., Osaka | Soy Saponins A ↓ 1 ↓ and A? 2? and their use |
JPS5933232A (en) | 1982-08-19 | 1984-02-23 | Tokiwa Kanpou Seiyaku:Kk | Separation of saponin and flavone from leguminous plant |
JPS5985265A (en) | 1982-11-04 | 1984-05-17 | Naganoken Kooridoufu Kogyo Kyodo Kumiai | Preparation of nutrient enriched food raw material |
US4557927A (en) | 1983-03-10 | 1985-12-10 | Kabushiki Kaisha Hoyashibara | Food products and process for producing same |
JPS6130593A (en) | 1984-07-20 | 1986-02-12 | Pelican:Kk | Method of extracting saponin component from soybeam hypocotyl |
JPS61100524A (en) | 1984-10-19 | 1986-05-19 | Junichi Iwamura | Method of separating saponin and flavone |
JPS6210018A (en) | 1985-07-04 | 1987-01-19 | Oruto Bioka Kenkyusho:Kk | Composition for suppressing obesity |
JPS62155082A (en) | 1985-12-27 | 1987-07-10 | Karupisu Shokuhin Kogyo Kk | Production of bifidus bacterium proliferation substance |
US4883788A (en) | 1986-06-06 | 1989-11-28 | Hauser-Kuhrts, Inc. | Method and composition for reducing serum cholesterol |
US4889921A (en) | 1987-04-29 | 1989-12-26 | The University Of Toronto Innovations Foundation | Production of rapeseed protein materials |
JPH01175942A (en) | 1987-12-28 | 1989-07-12 | Sanyo Kokusaku Pulp Co Ltd | Antiviral composition for pharmaceutical use |
JPH01312965A (en) | 1988-06-13 | 1989-12-18 | Toshiko Miyazaki | Soybean-containing toasted green tea |
IT1219732B (en) | 1988-06-28 | 1990-05-24 | Tecnofarmaci Spa | PROCYANIDOLIC OLIGOMERIC FRACTIONS, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
JPH02188598A (en) | 1989-01-17 | 1990-07-24 | Nippon Mektron Ltd | Production of soyasaponin i |
JPH02261365A (en) | 1989-03-28 | 1990-10-24 | N I Inst Sadovodstva Vinogradars I Vinoderia | Soft drink for sthenia |
ATE96908T1 (en) | 1989-06-22 | 1993-11-15 | Univ Catholique Louvain | METHOD AND DEVICE FOR THE PREPARATION OF SAMPLES FOR THE CHEMICAL ANALYSIS OF LIQUIDS BY INFRARED SPECTROMETRY OF DRY EXTRACTS. |
GB2233450B (en) | 1989-06-24 | 1993-06-30 | Univ Wales Medicine | Detecting or quantifing multiple analytes with luminescent reagents |
CH679584A5 (en) * | 1989-11-10 | 1992-03-13 | Nestle Sa | |
JPH04152845A (en) | 1990-10-15 | 1992-05-26 | Shigekazu Ishimura | Coffee blended with soybean |
JPH05170756A (en) * | 1991-12-20 | 1993-07-09 | Kikkoman Corp | Production of isoflavone compound |
CA2136233C (en) * | 1992-05-19 | 2004-03-30 | Graham Edmund Kelly | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
CN1080864A (en) * | 1993-06-28 | 1994-01-19 | 沈阳药学院 | A kind of alcohol-decomposing powder and preparation method thereof |
CN1080863A (en) * | 1993-06-28 | 1994-01-19 | 沈阳药学院 | A kind of health medicine compositions of relieving the effect of alcohol |
DE4325532A1 (en) | 1993-07-29 | 1995-02-02 | Schwabe Willmar | Preparations of Crataegus species, medicinal products and their use for the prevention of sudden cardiac death and reperfusion-related cardiovascular damage |
US5637561A (en) * | 1993-10-12 | 1997-06-10 | Protein Technologies International, Inc. | Aglucone isoflavone enriched vegetable protein whey, whey protein, and process for producing |
WO1995010530A1 (en) * | 1993-10-12 | 1995-04-20 | Protein Technologies International, Inc. | An aglucone isoflavone enriched vegetable protein extract and isolate and process for producing |
DE69429673T3 (en) * | 1993-10-12 | 2007-08-23 | Archer Daniels Midland Co., Decatur | An AGLUKON ISOFLAVON ENRICHED PLANT PROTEIN CONCENTRATE AND A METHOD OF MANUFACTURING THEREOF |
US5320949A (en) * | 1993-10-12 | 1994-06-14 | Protein Technologies International, Inc. | Process for producing aglucone isoflavone enriched vegetable protein fiber |
JPH07147903A (en) | 1993-11-29 | 1995-06-13 | Yamamoto Housuien:Kk | Food containing tea leaf |
CA2128293C (en) * | 1993-12-06 | 2002-09-03 | Masayuki Tanabe | Fruit polyphenols and medicinal compositions containing them |
IT1265312B1 (en) * | 1993-12-21 | 1996-10-31 | Indena Spa | FORMULATIONS CONTAINING CAROTENOIDS AND PRO-CAROTENOIDS ASSOCIATED WITH POLYPHENOLS IN THE PREVENTION OF DAMAGES FROM ABNORMAL PRODUCTION OF |
US5506211A (en) | 1994-05-09 | 1996-04-09 | The Uab Research Foundation | Genistein for use in inhibiting osteroclasts |
US5424331A (en) * | 1994-06-10 | 1995-06-13 | Bio-Virus Research Incorporated | Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis |
JPH0873369A (en) | 1994-09-01 | 1996-03-19 | Fuairudo:Kk | Tea for health |
US5554645A (en) | 1994-10-03 | 1996-09-10 | Mars, Incorporated | Antineoplastic cocoa extracts and methods for making and using the same |
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5679806A (en) * | 1995-02-24 | 1997-10-21 | Hauser, Inc. | Process for the isolation and purification of isoflavones |
US5486631A (en) | 1995-06-14 | 1996-01-23 | Siltech Inc. | Silicone polymers for the modification of zinc oxide |
US5554519A (en) | 1995-08-07 | 1996-09-10 | Fermalogic, Inc. | Process of preparing genistein |
IL115110A (en) | 1995-08-30 | 1997-08-14 | Chajuss Daniel | Soy molasses |
US5968516A (en) * | 1995-10-03 | 1999-10-19 | Liu; Yaguang | Soybean drug and new method of extracting soybean saponins |
AU2100997A (en) | 1996-03-08 | 1997-09-22 | Energiser Plc | Composition containing iso-flavonoids and lignans |
US6033714A (en) | 1996-03-13 | 2000-03-07 | Archer Daniels Midland Company | Process for production of isoflavone fractions from soy |
US5702752A (en) | 1996-03-13 | 1997-12-30 | Archer Daniels Midland Company | Production of isoflavone enriched fractions from soy protein extracts |
US6391310B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of neurological symptoms |
US6171638B1 (en) | 1996-03-13 | 2001-01-09 | Archer Daniels Midland Company | Production of isoflavone enriched fractions from soy protein extracts |
WO1998043498A1 (en) | 1997-04-01 | 1998-10-08 | Nichimo Co., Ltd. | Product comprising health-promotive ingredient and process for producing the same |
WO1997037549A1 (en) | 1996-04-10 | 1997-10-16 | Nichimo Co., Ltd. | Substance containing health-promoting component and process for the production thereof |
WO1998003084A1 (en) | 1996-07-18 | 1998-01-29 | Nutricor, Inc. | Nutritious food preparations and methods for making them |
JP3424476B2 (en) | 1996-11-05 | 2003-07-07 | 不二製油株式会社 | Drinking material |
JP3883018B2 (en) * | 1997-02-06 | 2007-02-21 | キッコーマン株式会社 | Method for producing isoflavone compound |
JPH10312965A (en) | 1997-05-13 | 1998-11-24 | Mitsubishi Heavy Ind Ltd | Plasma chemical deposition system |
JP3998293B2 (en) | 1997-06-18 | 2007-10-24 | 株式会社ヤクルト本社 | Helicobacter pylori inhibitor |
WO1999006057A1 (en) * | 1997-07-30 | 1999-02-11 | Indena S.P.A. | Soya extract, process for its preparation and pharmaceutical composition |
US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
US5904924A (en) * | 1997-11-04 | 1999-05-18 | Oncologics, Inc. | Green nutritional powder composition |
EP1051171A1 (en) * | 1998-01-28 | 2000-11-15 | Dusan Miljkovic | Isoflavanoid formulations for oral administration |
US6121010A (en) * | 1998-05-12 | 2000-09-19 | The Endowment For Research In Human Biology | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
DE69916414T2 (en) | 1998-07-16 | 2005-05-19 | Aaron Tabor | SOY PREPARATIONS AND THEIR USE IN HEALTH PROMOTION |
JP2000095792A (en) * | 1998-09-21 | 2000-04-04 | Showa Sangyo Co Ltd | Acquisition of isoflavone composition comprising genistin |
WO2002052063A1 (en) | 2000-12-21 | 2002-07-04 | Mccomas Technologies Ag | Coating compositions containing nickel and boron and particles |
-
1998
- 1998-09-28 US US09/162,038 patent/US6261565B1/en not_active Expired - Lifetime
- 1998-10-01 IL IL126433A patent/IL126433A/en not_active IP Right Cessation
- 1998-10-01 AU AU87879/98A patent/AU748832B2/en not_active Ceased
- 1998-10-01 NZ NZ332131A patent/NZ332131A/en unknown
- 1998-10-01 CA CA002249501A patent/CA2249501C/en not_active Expired - Lifetime
- 1998-10-01 NO NO984591A patent/NO318696B1/en unknown
- 1998-10-02 KR KR1019980041946A patent/KR19990066785A/en not_active Application Discontinuation
- 1998-10-02 EP EP98308060A patent/EP0906761B1/en not_active Expired - Lifetime
- 1998-10-02 ES ES98308060T patent/ES2224337T3/en not_active Expired - Lifetime
- 1998-10-02 ES ES04015530T patent/ES2333866T3/en not_active Expired - Lifetime
- 1998-10-02 DK DK98308060T patent/DK0906761T3/en active
- 1998-10-02 AT AT98308060T patent/ATE270894T1/en active
- 1998-10-02 PT PT98308060T patent/PT906761E/en unknown
- 1998-10-02 AT AT04015530T patent/ATE443521T1/en not_active IP Right Cessation
- 1998-10-02 EP EP04015530A patent/EP1466609B1/en not_active Expired - Lifetime
- 1998-10-02 DE DE69825003T patent/DE69825003T2/en not_active Expired - Lifetime
- 1998-10-02 JP JP10296187A patent/JPH11221048A/en active Pending
-
1999
- 1999-01-14 TW TW087116374A patent/TWI241893B/en not_active IP Right Cessation
- 1999-04-27 HK HK99101886A patent/HK1016879A1/en not_active IP Right Cessation
-
2000
- 2000-07-13 US US09/616,150 patent/US6395279B1/en not_active Expired - Fee Related
- 2000-07-13 US US09/615,152 patent/US6399072B1/en not_active Expired - Fee Related
- 2000-07-13 US US09/615,239 patent/US6391308B1/en not_active Expired - Fee Related
- 2000-07-13 US US09/615,240 patent/US6391309B1/en not_active Expired - Lifetime
-
2001
- 2001-06-28 KR KR1020010037277A patent/KR20010071086A/en not_active Application Discontinuation
-
2002
- 2002-05-01 US US10/136,150 patent/US6518319B1/en not_active Expired - Lifetime
- 2002-05-01 US US10/136,103 patent/US20020168433A1/en not_active Abandoned
- 2002-05-01 US US10/137,490 patent/US6900240B2/en not_active Expired - Fee Related
- 2002-05-01 US US10/136,079 patent/US20030064938A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808574A (en) * | 1986-12-03 | 1989-02-28 | Nauchno-Issledovatelsky Institut Sadovodstva | Composition inhibiting pathological addiction to alcohol |
US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
US5624910A (en) * | 1991-07-01 | 1997-04-29 | The Endowment For Research In Human Biology, Inc. | Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse |
US5547671A (en) * | 1995-09-20 | 1996-08-20 | Duthinh; Phu | Anti-intoxication composition |
US5837256A (en) * | 1995-12-21 | 1998-11-17 | Clark; William F. | Method for treatment of Lupus nephritis |
US6399072B1 (en) * | 1996-03-13 | 2002-06-04 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of alcoholism |
US20030064938A1 (en) * | 1996-03-13 | 2003-04-03 | Mark Empie | Method of preparing and using compositions extracted from vegetable matter for the treatment of cardiovascular conditions |
US20030180404A1 (en) * | 1999-04-20 | 2003-09-25 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030064938A1 (en) * | 1996-03-13 | 2003-04-03 | Mark Empie | Method of preparing and using compositions extracted from vegetable matter for the treatment of cardiovascular conditions |
US20030180436A1 (en) * | 2002-03-22 | 2003-09-25 | Pizzey Glenn Roy | High lignan flaxseed product and product by process |
US7048960B2 (en) | 2002-03-22 | 2006-05-23 | Glenn Roy Pizzey | High lignan flaxseed product and product by process |
US20060210691A1 (en) * | 2005-03-15 | 2006-09-21 | Pizzey Glenn R | Methods of increasing flaxseed hull recovery and resultant flax products |
US7595078B2 (en) | 2005-03-15 | 2009-09-29 | Glanbia Nutritionals Ireland Limited | Methods of increasing flaxseed hull recovery and resultant flax products |
US20080260924A1 (en) * | 2007-04-20 | 2008-10-23 | Liang-Rong Chen | Composition Comprising Five Kinds of Processed Fruit or Vegetables |
WO2010075418A2 (en) * | 2008-12-23 | 2010-07-01 | The Administrators Of The Tulane Educational Fund | Glyceollins suppress androgen-responsive prostate cancer |
WO2010075418A3 (en) * | 2008-12-23 | 2010-09-30 | The Administrators Of The Tulane Educational Fund | Glyceollins suppress androgen-responsive prostate cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU748832B2 (en) | Method of preparing and using isoflavones | |
US6509381B2 (en) | Method of preparing and using compositions extracted from vegetable matter for the treatment of neurological conditions | |
WO1994023716A1 (en) | Method for treatment of menopausal and premenstrual symptoms | |
KR100877604B1 (en) | Composition comprising an extract of processed ginseng for preventing and treating obesity | |
US6264997B1 (en) | Anti-arteriosclerotic food | |
CN100366628C (en) | Effective parts of fructus sophorae flavone production and use thereof | |
EP2133080A1 (en) | Compounds containing equol | |
TWI260205B (en) | A composition including isoflavones refined from plant | |
MXPA98008146A (en) | Method of preparation and use of isoflavo | |
KR101791574B1 (en) | Pharmaceutical composition for preventing or treating female menopausal disorder comprising an extract of black rice aleurone layer | |
KR20040006823A (en) | A healthful food with anti-oxidative function and manufacturing method thereof | |
KR101472224B1 (en) | Composition for preventing and treating of osteoporosis comprising root extract of Rumex Crispus L. | |
Udgata et al. | Soybean isoflavones: Remedial nutraceuticals in Indian perspective | |
KR101543998B1 (en) | Composition for treating and improving fatty liver and hyperlipidemia comprising extract of olive as an active ingredient | |
DE10204634A1 (en) | Composition useful as a food or food supplement, and for treating e.g. tumors or osteoporosis, contains isoflavone, lignan and phytosterol | |
KR19990079922A (en) | Lipid metabolism improving and blood pressure lowering composition comprising jujube extract and citrus peel extract | |
DE20221674U1 (en) | Composition useful as a food or food supplement, and for treating e.g. tumors or osteoporosis, contains isoflavone, lignan and phytosterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |